What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2024-03-12 compared with 2023-03-07 · 891 added, 811 removed, 601 unchanged (74% of the section changed)

1 unchanged sentence

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s regulations, rules and forms and that such information is accumulated and communicated to our management, including our principal officers, as appropriate, to allow for timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) promulgated by the SEC under the Exchange Act,

we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K.

Based on the foregoing, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Annual Report on Form 10-K as a result of the material weakness described below.

No Management Assessment Regarding Internal Control Over Financial Reporting or Attestation Report of Registered Public Accounting Firm

This Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting (“ICFR”) as allowed by the SEC for reverse acquisitions between an issuer and a private operating company when it is not possible to conduct an assessment of the private operating company’s ICFR in the period between the consummation date of the reverse acquisition and the date of management’s assessment of ICFR (see Section 215.02 of the SEC Division of Corporation Finance’s Regulation S-K Compliance & Disclosure Interpretations).

We completed the Business Combination on November 10, 2022, pursuant to which we acquired Legacy Scilex and its subsidiaries.

Prior to the Business Combination, we were a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses.

As a result, previously existing internal controls are no longer applicable or comprehensive enough as of the assessment date as our operations prior to the Business Combination were insignificant compared to those of the consolidated entity post-Business Combination.

The design of ICFR for the Company post-Business Combination has required and will continue to require significant time and resources from management and other personnel.

As a result, management was unable, without incurring unreasonable effort or expense, to conduct an assessment of our ICFR as of December 31, 2022.

The Company intends to conduct a management assessment regarding ICFR as of December 31, 2023.

This Annual Report also does not contain an attestation report of our registered public accounting firm regarding ICFR since the Company, as an “emerging growth company,”

is not required to provide such report.

As required by Rule 13a-15(b) promulgated by the SEC under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K.

Based on the foregoing, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.

Remediation of Previously Reported Material Weaknesses

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting (“ICFR”), such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected

on a timely basis.

As previously reported in Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, management identified a material weakness in our ICFR.

The material weakness related to a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas.

As a result, we identified that certain of our control activities in the areas of revenues, debt, business combination and derivative liabilities did not operate effectively and therefore, were deficient and the combination of the aforementioned deficiencies were deemed to represent a material weakness in our ICFR as of December 31, 2022.

In response to the material weaknesses, and as previously disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2022, we implemented the following additional measures as part of the remediation process:

(i) recruiting and employing personnel with appropriate experience and technical expertise to enhance management’s assessment of judgmental and technical accounting areas,

(ii) conducting additional training for staff involved in judgmental and technical accounting areas, and

(iii) engaging additional independent third-party technical consultants to assist in performing accounting analyses of complex transactions.

The applicable measures have been implemented for a sufficient period of time and management has concluded, through testing, that the enhanced controls are operating effectively, and that the material weakness was remediated as of December 31, 2023.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate ICFR as defined in Rules 13a-15(f) under the Exchange Act.

Our ICFR is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.

Under the supervision of and with the participation of our Principal Executive Officer and Principal Financial Officer, our management assessed the effectiveness of our ICFR as of December 31, 2023, based on the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on this assessment, management has concluded that our ICFR was effective as of December 31, 2023.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our ICFR.

Management’s report was not subject to attestation by the Company’s registered public accounting firm because the JOBS Act permits emerging growth companies such as our company to provide only management’s report in the Annual Report on Form 10-K.

Inherent Limitations on Effectiveness of Controls

Because of its inherent limitations, ICFR may not prevent or detect misstatements.

Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Despite not conducting a formal assessment regarding ICFR, management concluded that we did not employ sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas.

As a result, we identified that certain of our control activities in the areas of revenue, debt, business combination and derivative liabilities did not operate effectively and therefore, were deficient and the combination of the aforementioned deficiencies were deemed to represent a material weakness in our internal control over financial reporting as of December 31, 2022.

While we have taken actions to remediate this material weakness, including (i) recruiting and employing personnel with appropriate experience and technical expertise to enhance management’s assessment of judgmental and technical accounting areas, (ii) conducting additional training for staff involved in judgmental and technical accounting areas, and (iii) engaging additional independent third-party technical consultants to assist in performing accounting analyses of complex transactions, completion of our remediation efforts is ongoing.

As such management has concluded the aforementioned material weakness has not been remediated as of December 31, 2022.

As a company with limited accounting resources, a significant amount of management’s time and attention has been and will be diverted from our business to ensure compliance with these regulatory requirements.

Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met.

Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

Other than in connection with the closing of the Business Combination, there were no changes in our internal control over financial reporting (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Other Inf ormation.

Not applicable.

Disclosure Regarding F oreign Jurisdictions that Prevent Inspections.

As described above, we have taken steps to remediate the material weaknesses in our ICFR.

Other than in connection with the remediation process described above, there were no changes in our ICFR (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our ICFR.

Other Information.

During the fourth quarter ended December 31, 2023, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

Directors, Executive O fficers and Corporate Governance.

The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

Directors, Executive Officers and Corporate Governance.

The information required by this item is incorporated by reference from the information contained in the Company’s definitive proxy statement relating to the 2024 Annual Meeting of Stockholders (the “2024 Proxy Statement”), which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 10.

2 unchanged sentences

To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 11.

Security Ownership of C ertain Beneficial Owners and Management and Related Stockholder Matters.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 12.

Certain Relationships and Rel ated Transactions, and Director Independence.

Certain Relationships and Related Transactions, and Director Independence.

3 unchanged sentences

To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 14.

Exhibits, F inancial Statement Schedules.

Exhibits, Financial Statement Schedules.

(a)(1) Financial Statements

4 unchanged sentences

(incorporated by reference to Exhibit 2.1 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 2.2 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on October June 27, 2022).

1 unchanged sentence

(incorporated by reference to Exhibit 2.3 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 2.4 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

1 unchanged sentence

I, Vickers Merger Sub, Inc.

and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 21, 2022).

2 unchanged sentences

I, Vickers Merger Sub, Inc.

and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 14, 2022).

6 unchanged sentences

Warrant Agreement, dated as of January 6, 2021, by and between Vickers Vantage Corp.

I and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 of Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 11, 2021).

Specimen Warrant Certificate of Scilex Holding Company (f/k/a Vickers Vantage Corp.

I) (incorporated by reference to Exhibit 4.3 of Vickers’s Form S-1 (File No.

333-251352), filed with the SEC on December 15, 2020).

Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc.

on September 21, 2023 (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Form of Scilex Holding Company Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Form of Common Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 5, 2024).

Form of Representative Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 5, 2024).

Description of Securities of Scilex Holding Company.

Amended and Restated Registration Rights Agreement, dated as of November 10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc.

and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on November 17, 2022).

Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.

2 unchanged sentences

Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC June 27, 2022).

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc.

2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC June 27, 2022).

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC June 27, 2022).

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC June 27, 2022).

Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on November 17, 2022).

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Scilex Holding Company 2022 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on May 5, 2023).

Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on Form 8-K (File No.

4 unchanged sentences

001-39852), filed with the SEC on November 17, 2022).

Sponsor Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp.

I and certain stockholders (incorporated by reference to Exhibit 10.1 of Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 21, 2022).

Amendment No.

1 to Sponsor Support Agreement, dated as of September 12, 2022, by and among Vickers Vantage Corp.

I and certain stockholders (incorporated by reference to Exhibit 10.2 of

Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 14, 2022).

Company Stockholder Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp.

I, Scilex Holding Company and Sorrento Therapeutics, Inc.

(incorporated by reference to Exhibit 10.2 of Vickers’s Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 21, 2022).

Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 17, 2023).

Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 17, 2023).

Form of Restricted Stock Unit Award Grant Notice and Award Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 17, 2023).

Offer Letter, dated as of April 19, 2019, between Scilex Pharmaceuticals Inc.

and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Offer Letter, dated as of April 27, 2022, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.21 of Amendment No.

1 of Vickers’s Form S-4 (File No.

Consulting Agreement, dated as of September 20, 2023, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 22, 2023).

Office Lease, dated as of August 8, 2019, by and between Scilex Pharmaceuticals Inc.

and 960 San Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

First Amendment to Office Lease, dated as of September 15, 2019, by and between Scilex Pharmaceuticals Inc.

and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

Amended and Restated Industrial Lease, dated as of April 12, 2023, by and between Scilex Pharmaceuticals, Inc.

and 960 San Antonio LLC (incorporated by reference to Exhibit 10.39 of Amendment No.

4 of Scilex’s Form S-1 (File No.

333-271401), filed with the SEC on June 29, 2023).

Sublease Agreement, dated as of May 18, 2022, by and between Scilex Holding Company and Live Action, Inc.

(incorporated by reference to Exhibit 10.61 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

Commercial Supply Agreement, dated as of February 16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd.

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 10.26 of Amendment No.

4 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on September 13, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 10.27 of Amendment No.

4 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on September 13, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 10.28 of Amendment No.

4 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on September 13, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 10.29 of Amendment No.

4 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on September 13, 2022).

1 unchanged sentence

(incorporated by reference to Exhibit 10.33 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

3 unchanged sentences

(incorporated by reference to Exhibit 10.34 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

First Amendment to Product Development Agreement, dated as of April 2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd.

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.

2 of Vickers’s Form S-4 (File No.

and Itochu Chemical Frontier Corporation (incorporated by

reference to Exhibit 10.35 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

1 unchanged sentence

and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

Master Services Agreement —

SP-102, dated as of January 27, 2017, by and between Semnur Pharmaceuticals, Inc.

Master Services Agreement - SP-102, dated as of January 27, 2017, by and between Semnur Pharmaceuticals, Inc.

and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

2 unchanged sentences

and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

2 unchanged sentences

(incorporated by reference to Exhibit 10.42 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

4 unchanged sentences

(incorporated by reference to Exhibit 10.43 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

License and Commercialization Agreement, dated as of June 14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Assignment Agreement, dated August 6, 2013, between Semnur Pharmaceuticals, Inc.

and Shah Investor LP (incorporated by reference to Exhibit 10.57 of Amendment No.

1 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on June 27, 2022).

Office Lease, dated as of August 8, 2019, by and between Scilex Pharmaceuticals Inc.

and 960 San Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

First Amendment to Office Lease, dated as of September 15, 2019, by and between Scilex Pharmaceuticals Inc.

and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

Sublease Agreement, dated as of May 18, 2022, by and between Scilex Holding Company and Live Action, Inc.

(incorporated by reference to Exhibit 10.61 of Amendment No.

2 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on July 21, 2022).

Stockholder Agreement, dated as of September 12, 2022, between Vickers Vantage Corp.

I and Sorrento Therapeutics, Inc.

(incorporated by reference to Exhibit 10.59 of Amendment No.

4 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on September 13, 2022).

Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 10.60 of Amendment No.

4 of Vickers’s Form S-4 (File No.

Securities Purchase Agreement, dated September 21, 2023, by and between Scilex Holding Company, Oramed Pharmaceuticals Inc.

and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Letter Agreement, dated October 17, 2022, between Scilex Holding Company and Sorrento Therapeutics, Inc.

(incorporated by reference to Exhibit 10.61 of Amendment No.

5 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on October 18, 2022).

Warrant Transfer Agreement, dated October 17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd and for the limited purposes set forth therein, Vickers Vantage Corp.

I and Maxim Group LLC.

(incorporated by reference to Exhibit 10.62 of Amendment No.

5 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on October 18, 2022).

Debt Contribution Agreement, dated October 17, 2022, by and among Vickers Vantage Corp.

I, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (incorporated by reference to Exhibit 10.63 of Amendment No.

5 of Vickers’s Form S-4 (File No.

333-264941), filed with the SEC on October 18, 2022).

Letter Agreement, dated October 17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Vickers Vantage Corp.

I and Maxim Group LLC.

(incorporated by reference to Exhibit 10.64 of Amendment No.

5 of Vickers’s Form S-4 (File No.

Convertible Debenture, dated as of March 21, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 21, 2023).

Convertible Debenture, dated as of April 11, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on April 11, 2023).

Convertible Debenture, dated as of April 20, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on April 20, 2023).

Amendment to Convertible Debenture, dated as of October 11, 2023, by and between Scilex Holding Company and YA II PN, Ltd.

(incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on October 11, 2023).

Standby Equity Purchase Agreement, dated as of November 17, 2022, by and between Scilex Holding Company and YA II PN, LTD.

Credit and Security Agreement, dated as of June 27, 2023, by and between Scilex Pharmaceuticals Inc.

and eCapital Healthcare Corp.

(incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on June 27, 2023).

Guaranty Agreement, dated as of June 27, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on June 27, 2023).

and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on November 17, 2022).

Standby Equity Purchase Agreement, dated as of January 8, 2023, by and between Scilex Holding Company and B.

Riley Principal Capital II, LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 9, 2023).

Amended and Restated Standby Equity Purchase Agreement, dated as of February 8, 2023, by and between Scilex Holding Company and YA II PN, LTD.

1 unchanged sentence

001-39852), filed with the SEC on February 9, 2023).

Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 17, 2023).

Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhbit 10.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on January 17, 2023).

List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Current Report on Form 8-K (File No.

Registration Rights Agreement, dated as of March 21, 2023, by and between Scilex Holding Company and YA II PN, LTD.

(incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 21, 2023).

Settlement Agreement, dated September 15, 2023, by and among Scilex Holding Company, Cove Lane Onshore Fund, LLC, HBC Investments LLC and Hudson Bay Capital Management LP (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 21, 2023).

Registration Rights Agreement, dated September 21, 2023, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc.

(incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Securities Purchase Agreement, dated September 21, 2023, by and between Scilex Holding Company, Oramed Pharmaceuticals Inc.

and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Subsidiary Guarantee, dated September 21, 2023, made by certain of the Company’s subsidiaries in favor of the holders of that certain Senior Secured Promissory Note dated as of the date thereof due March 21, 2025 in the original aggregate principal amount of $101,875,000 (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Security Agreement, dated September 21, 2023, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc.

and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.4 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Subordination Agreement, dated September 21, 2023, by and among eCapital Health Corp., Scilex Pharmaceuticals Inc.

and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.5 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Stock Purchase Agreement, dated September 21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc.

(incorporated by reference to Exhibit 10.6 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Assignment, Assumption and Release Agreement, dated September 21, 2023, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc.

and Scintilla Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 10.7 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Letter Agreement, dated September 21, 2023, by and among Scilex Holding Company, Sorrento Therapeutics, Inc.

and Scintilla Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 10.8 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Letter Agreement, dated September 21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc.

(incorporated by reference to Exhibit 10.9 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on September 26, 2023).

Underwriting Agreement, dated February 29, 2024, among Scilex Holding Company, Rodman & Renshaw LLC and StockBlock Securities LLC.

(incorporated by reference to Exhibit 1.1 of our Current Report on Form 8-K (File No.

001-39852), filed with the SEC on March 5, 2024).

Severance and Change of Control Agreement, dated as of November 8, 2023, by and between Jaisim Shah and Scilex Holding Company (incorporated by reference to Exhibit 10.12 of our Quarterly Report on Form 10-Q (File No.

001-39852), filed with the SEC on November 14, 2023).

Consent of Ernst & Young LLP, independent registered public accounting firm of Scilex Holding Company.

Severance and Change of Control Agreement, dated as of November 9, 2023, by and between Henry Ji and Scilex Holding Company (incorporated by reference to Exhibit 10.13 of our Quarterly Report on Form 10-Q (File No.

001-39852), filed with the SEC on November 14, 2023).

Severance and Change of Control Agreement, dated as of November 8, 2023, by and between Stephen Ma and Scilex Holding Company (incorporated by reference to Exhibit 10.14 of our Quarterly Report on Form 10-Q (File No.

001-39852), filed with the SEC on November 14, 2023).

Scilex Holding Company Insider Trading Policy.

List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Form S-1 (File No.

333-275117), filed with the SEC on October 20, 2023).

Consent of Ernst & Young LLP, independent registered public accounting firm.

Power of Attorney (included on the signature page hereto).

Certification of Jaisim Shah, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Elizabeth Czerepak, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Jaisim Shah, Principal Executive Officer, and Elizabeth Czerepak, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Certification of Stephen Ma, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Jaisim Shah, Principal Executive Officer, and Stephen Ma, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Scilex Holding Company Clawback Policy.

Inline XBRL Instance Document.

17 unchanged sentences

Chief Executive Officer and President

(Principal Executive Officer)

March 11, 2024

/s/ Stephen Ma

Chief Financial Officer

(Principal Financial Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, each of Jaisim Shah and Elizabeth Czerepak, acting alone or together with another attorney-in-fact, as his or her attorney-in-fact, with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, each of Jaisim Shah and Stephen Ma, acting alone or together with another attorney-in-fact, as his attorney-in-fact, with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

3 unchanged sentences

(Principal Executive Officer)

/s/ Elizabeth A.

Executive Vice President, Chief Financial Officer and Chief Business Officer

( Principal Financial Officer)

/s/ Stephen Ma

Chief Financial Officer

March 11, 2024

(Principal Financial and Accounting Officer)

/s/ Henry Ji, Ph.D.

6 unchanged sentences

March 11, 2024

/s/ Tien-Li Lee, M.D.

March 7, 2023

Tien-Li Lee, M.D.

Jay Chun, M.D., Ph.D.

/s/ David Lemus

March 11, 2024

/s/ Tommy Thompson

/s/ Yue Alexander Wu

March 11, 2024

Tommy Thompson

Yue Alexander Wu, Ph.D.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

2 unchanged sentences

Consolidated Statements of Operations for the Years ended December 31, 2023, 2022 and 2021

Consolidated Statements of Stockholders’

Equity / (Deficit) for the Years ended December 31, 2022, 2021, and 2020

Consolidated Statements of Stockholders’ (Deficit) / Equity for the Years ended December 31, 2023, 2022 and 2021

Consolidated Statements of Cash Flows for the Years ended December 31, 2023, 2022 and 2021

4 unchanged sentences

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders' equity/(deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”).

We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ (deficit)/equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S.

2 unchanged sentences

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

As discussed in Note 2 to the financial statements, the Company has negative working capital, has suffered losses from operations, has recurring negative cash flows from operations, and has stated that substantial doubt exists about the Company’s ability to continue as a going concern.

Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2.

Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2.

The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

1 unchanged sentence

These financial statements are the responsibility of the Company’s management.

Our responsibility is to express an opinion on the Company’s financial statements based on our audits.

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.

10 unchanged sentences

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2020.

San Diego, California

March 11, 2024

PART I—FIN ANCIAL INFORMATION

Fin ancial Statements

SCILEX HOLDING COMPANY

CONSOLIDATED BALANC E SHEETS

AS OF DECEMBER 31, 2022 AND 2021

CONSOLIDATED BALANCE SHEETS

(In thousands, except for par value and share amounts)

December 31, 2022

December 31, 2021

Current assets:

7 unchanged sentences

Other long-term assets

LIABILITIES AND STOCKHOLDERS’

EQUITY/(DEFICIT)

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY

Current liabilities:

4 unchanged sentences

Current portion of deferred consideration

Current portion of debt

Related party payable

Related party note payable

Debt, current

Current portion of operating lease liabilities

1 unchanged sentence

Long-term portion of deferred consideration

Long-term debt, net

Related party note payable, net

Debt, net of issuance costs

Derivative liabilities

3 unchanged sentences

Commitments and contingencies (See Note 11)

Stockholders’

equity/(deficit):

Stockholders’ (deficit) equity:

Preferred stock, $ 0.0001 par value, 45,000,000 shares authorized;

29,057,097 and 0 issued and outstanding at December 31, 2022 and December 31, 2021, respectively

29,057,097 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively

Common stock, $ 0.0001 par value, 740,000,000 shares authorized;

141,348,856 and 132,858,484 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively

160,084,250 shares issued and 100,015,665 shares outstanding as of December 31, 2023;

141,348,856 shares issued and outstanding as of December 31, 2022

Additional paid-in capital

Accumulated deficit

Total stockholders’

equity/(deficit)

Total liabilities and stockholders’

equity/(deficit)

Treasury stock, at cost;

60,068,585 shares and nil shares as of December 31, 2023 and December 31, 2022, respectively

Total stockholders’ (deficit) equity

Total liabilities and stockholders’ (deficit) equity

See accompanying notes to audited consolidated financial statements

1 unchanged sentence

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020

(In thousands, except for net loss per share amounts)

8 unchanged sentences

Other (income) expense:

(Gain) loss on derivative liability

Loss (gain) on derivative liability

Change in fair value of debt and liability instruments

(Gain) loss on debt extinguishment, net

Scilex Pharma Notes principal increase

Interest expense

Loss (gain) on foreign currency exchange

Interest expense, net

Loss on foreign currency exchange

Total other (income) expense

Loss before income taxes

Income tax expense (benefit)

Net loss per share attributable to common stockholders—basic and diluted

Weighted average number of shares during the period—basic and diluted

Income tax expense

Net loss per share attributable to common stockholders — basic and diluted

Weighted average number of shares during the period — basic and diluted

See accompanying notes to audited consolidated financial statements

SCILEX HOLDING COMPANY

CONSOLIDATED STATEMENTS OF STOCK HOLDERS’

EQUITY / (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) / EQUITY

(In thousands)

Legacy Common Stock

Preferred Stock

Treasury Stock

Stockholders’

Paid-in Capital

Balance, December 31, 2019

Retroactive application of the recapitalization due to the Business Combination

Balance at December 31, 2019, after the effect of Business Combination

Stock options exercised

Stock-based compensation

Distribution to Sorrento

Cancellation of shares held in escrow related to Semnur Acquisition

(Deficit) Equity

Balance, December 31, 2020

10 unchanged sentences

Balance, December 31, 2022

Shares issued under Standby Equity Purchase Agreements

Disbursement of funds to Sorrento

Repurchase of Treasury Stock, Preferred Stock, and warrants

Issuance of Penny Warrants

Issuance of common stock in connection with Settlement Agreement

Conversion of Convertible Debentures into common stock

Retainer shares issued

Issuance of common stock upon warrants exercise

Stock options exercised

Stock-based compensation

Balance, December 31, 2023

See accompanying notes to audited consolidated financial statements

SCILEX HOLDING COMPANY

CONSOLIDATED STATEMENTS OF CASH FL OWS

FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

9 unchanged sentences

Stock-based compensation

(Gain) loss on derivative liability

Issuance of shares under Settlement Agreement

Loss (gain) on derivative liability

Forfeitures of private warrants

Change in fair value of debt and liability instruments

Changes in operating assets and liabilities:

15 unchanged sentences

Financing activities

Proceeds from the Business Combination

Proceeds from issuance of shares under Standby Equity Purchase Agreements

Proceeds from issuance of Convertible Debentures

Repayment of Convertible Debentures

Proceeds from issuance of Revolving Facility

Repayment of Revolving Facility

Repayment of Oramed Note

Transaction costs paid related to the Business Combination

Repayment of principal on the Scilex Pharma Notes

Repayment on other loans

Proceeds from other loans

Proceeds from stock options exercised

Payments of debt issuance costs

Disbursement of funds to Sorrento

Cash consideration paid in connection with share repurchase

Transaction costs paid in connection with share repurchase

Proceeds from the Business Combination

Proceeds from stock options and warrants exercised

Proceeds from related party payable

Proceeds from related party note payable

Net cash provided by financing activities

Net change in cash and cash equivalents

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

Supplemental disclosures:

Supplemental disclosures of non-cash investing and financing activities

Proceeds from other loans

Repayment of principal on the Scilex Pharma Notes

Repayment on other loans

Net cash proceeds from financing activities

Net change in cash, cash equivalents and restricted cash

Cash, cash equivalents and restricted cash at beginning of period

Cash, cash equivalents and restricted cash at end of period

Supplemental disclosure:

Cash paid for interest

Non-cash investing and financing activities

Issuance of shares to B.

Riley pursuant to B.

Riley Purchase Agreement

Conversion of Convertible Debentures into common stock

Right-of-use assets obtained in exchange for operating lease liabilities with lease modification

Oramed Note issuance at fair value

Year Ended December 31,

Other non-cash consideration in connection with share repurchase

Excise tax in connection with share repurchase included in accrued expenses

Related party debt converted to equity pursuant to Debt Exchange Agreement

Deferred consideration for Romeg intangible asset acquisition

Non-cash consideration in Semnur acquisition

Other loan forgiveness

Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount

Promissory Note issued to Sorrento in exchange for the SP-104 license

Fair value adjustment to derivative liability in troubled debt restructuring

Acquisition of right-of-use asset

Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement

Non-cash distribution to Sorrento

Scilex Pharma Notes principal increase

Accrual for transaction costs related to the Business Combination

Transaction costs obligation assumed by Sorrento

1 unchanged sentence

SCILEX HOLDING COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATE D FINANCIAL STATEMENTS

Nature of Operations and Basis of Presentation

Organization and Principal Activities

Scilex Holding Company (“Scilex”

and together with its wholly owned subsidiaries, the “Company”) is the successor entity to Vickers Vantage Corp.

I (“Vickers”).

Vickers was formed on February 21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

Scilex was originally formed in 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc.

(“Sorrento”).

Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc.

(“Scilex Pharma”) and Semnur Pharmaceuticals, Inc.

(“Semnur”).

The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain.

The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.

The Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S.

(see Note 2).

The Company is planning to commercialize GLOPERBA in 2023.

The Company is currently developing three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica (“SP-102”

or “SEMDEXA”), SP-103 (lidocaine topical system) 5.4% (“SP-103”), for the treatment of acute low back pain, and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel formulation for the treatment of fibromyalgia.

Since inception, the Company has devoted substantially all of its efforts to the development of SP-102, SP-103, SP-104, and the commercialization of ZTlido.

The Business Combination

On March 17, 2022, Scilex entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (“Vickers Merger Sub”).

Pursuant to the terms of the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc.

(f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (“Legacy Scilex"), with Legacy Scilex surviving the merger and becoming a wholly-owned subsidiary of Vickers (collectively, the “Business Combination”).

On November 10, 2022, Vickers consummated the Business Combination pursuant to the terms of the Merger Agreement.

Vickers acquired all of the outstanding equity interests of Legacy Scilex.

As a result of the Business Combination, Scilex received net proceeds of approximately $ 3.4 million .

Additionally, all existing related party indebtedness between Legacy Scilex and Sorrento totaling $ 290.6 million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12).

The Company, as the successor entity of Vickers, will operate as “Scilex Holding Company”

and was listed on the Nasdaq Capital Market under the new ticker symbol “SCLX”

on November 11, 2022.

At the closing of the Business Combination, 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock (“Legacy Scilex Common Stock”) and Legacy Scilex stock options, respectively, were converted to 133,060,534

shares of Common Stock (“Common Stock”) as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock (the “Common Stock Exchange Ratio”) and 16,939,436 shares of Common Stock were reserved for Legacy Scilex optionholders.

Pursuant to the terms of the Debt Exchange Agreement (see Note 12), $ 290.6 million was converted to 29,057,097 shares of Preferred Stock (“Preferred Stock”) and 2,905,710 shares of Common Stock.

In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd (“Sponsors”) and Vickers (“Vickers Debt Agreement”), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (“Working Capital Loans”) at the closing of the Business Combination of $ 5,330,557 was converted to 533,057 shares of Common Stock.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S.

Under this method of accounting, Vickers was treated as the “acquired”

company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization.

Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded.

The Company’s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and other current assets on the consolidated balance sheets, of which $ 9.1 million has been offset against the equity proceeds in the Business Combination and $ 0.4 million was attributed to the liability-classified Private Warrants and, as such, were expensed upon the closing of the Business Combination.

Scilex Holding Company (“Scilex” and together with its wholly owned subsidiaries, the “Company”) is the successor entity to Vickers Vantage Corp.

I (“Vickers”), a special purpose acquisition company.

The Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.

The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc.

(“Legacy Scilex”), Scilex Pharmaceuticals Inc.

(“Scilex Pharma”), Semnur Pharmaceuticals, Inc.

(“Semnur”), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC.

The business combination with Vickers (the “Business Combination”) was closed in November 2022.

The Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (“GLOPERBA”), a U.S.

Food and Drug Administration (“FDA”)-approved prophylactic treatment for painful gout flares in adults, in the United States (“U.S.”).

In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (“ELYXYB”) and the commercialization thereof in the U.S.

ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

In April 2023, the Company launched ELYXYB in the U.S.

The Company expects to commercialize GLOPERBA in the U.S.

in the first half of 2024.

The Company is currently developing three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study (“SP-102” or “SEMDEXA”), SP-103 (lidocaine topical system) 5.4% (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company has recently completed a Phase 2 trial in low back pain, and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024.

Since inception, the Company has devoted substantially all of its efforts to the development of SP-102, SP-103 and SP-104, and the commercialization of ZTlido.

In 2024, the Company will also devote efforts on the commercialization of GLOPERBA and ELYXYB.

Sorrento Chapter 11 Filing

On February 13, 2023, Sorrento Therapeutics, Inc.

(“Sorrento”), the Company’s then-controlling stockholder, and Sorrento’s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc.

(“Scintilla” and together with Sorrento, the “Debtors”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).

The Debtors’ Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number 23-90085 (DRJ) (the “Chapter 11 Cases”).

While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases.

As of December 31, 2023, Sorrento no longer holds a majority of the voting power of the Company’s outstanding capital stock entitled to vote.

As of December 31, 2023, the Company had a $ 3.2 million receivable from Sorrento, which was fully reserved.

The Company evaluates the collectability of this receivable on a quarterly basis.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.

GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.

GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.

The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries.

All intercompany balances and transactions have been eliminated in consolidation.

Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance.

The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions.

The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.

Accordingly, the Company has determined that it operates its business as a single reportable segment.

Use of Estimates

The preparation of these consolidated financial statements in conformity with U.S.

GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period.

GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period.

Management believes that these estimates are reasonable;

however, actual results may differ from these estimates.

Customer Concentration Risk

Prior to April 2022, sales to the Company’s sole distributor represented 100 % of net revenue.

In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies.

The Company had three and four customers during the years ended December 31, 2023 and 2022 , respectively, each of which individually generated 10 % or more of the Company’s total revenue.

These customers accounted for 85 % and 83 % of the Company’s revenue for the years ended December 31, 2023 and 2022, respectively, individually ranging from 22 % to 32 % and 19 % to 24 %, respectively.

As of December 31, 2023 and 2022, these customers represented 91 % and 90 % of the Company’s outstanding accounts receivable, respectively, individually ranging between 24 % and 36 % for both periods.

Additionally, during the years ended December 31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (“Itochu”).

This exposes the Company to concentration of customer and supplier risk.

The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December 31, 2023 and 2022 .

Fair Value Measurements

Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets.

The carrying values of the Company’s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments.

The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4.

The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $ 25.0 million that were issued in March and April 2023 and for the Oramed Note (as defined below) in the principal amount of $ 101.9 million that was issued in September 2023 (see Note 7 titled “ Debt” below).

These instruments are measured at fair value on a recurring basis using Level 3 inputs.

The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively.

The Revolving Facility (as defined below) in an aggregate principal amount of up to $ 30.0 million was issued in June 2023 (see Note 7 titled “ Debt” below).

The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method.

The carrying value of the Revolving Facility approximates its fair value.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.

Assets and liabilities recorded at fair value are categorized based

upon the level of judgment associated with the inputs used to measure their fair value.

Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows:

Level 1 - Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2 - Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable inputs for similar assets or liabilities.

These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active;

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents.

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value.

Restricted cash as of December 31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June 27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7.

Restricted cash is recorded as other long-term assets within the Company’s consolidated balance sheet.

T he following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands):

Cash and cash equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.

Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.

Fair Value of Financial Instruments

The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.

Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.

Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability.

The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values.

Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

As of December 31, 2022 and 2021 , the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.

Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.

Restricted cash

Total cash, cash equivalents, and restricted cash

Accounts Receivable, Net

8 unchanged sentences

Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred.

When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management’s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval.

As of December 31, 2022 and 2021 , the Company’s inventory was primarily comprised of finished goods.

As of December 31, 2023 and 2022 , the Company’s inventory was primarily comprised of finished goods.

Property and Equipment, Net

3 unchanged sentences

The cost of repairs and maintenance is expensed as incurred.

The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (“IPR&D”) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets.

Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill.

19 unchanged sentences

The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review.

Recoverability is measured by comparison of the assets’

book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate.

Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate.

If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.

3 unchanged sentences

Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations.

Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging , contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.

Public Warrants and Private Placement Warrants

Upon completion of the Business Combination, the Company assumed public and private placement warrants (“Public Warrants”

and “Private Warrants”) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (“SEC”) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.

Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.

Public Warrants and Private Warrants

Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $ 11.50 per share (“Public Warrants” and “Private Warrants”, respectively, and collectively, the “SPAC Warrants”) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (“SEC”) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.

Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No.

815-40, Contracts on an Entity’s Own Equity .

815-40, Contracts on an Entity’s Own Equity.

Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.

Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40.

The Private Warrants are not considered indexed to the Company’s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract.

Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations.

The Company estimates the value of these warrants using a Black-Scholes option pricing formula.

The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.

The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates.

This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.

Convertible Debentures and the Oramed Note

The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 “ Liquidity and Going Concern ” below) that were issued in March and April 2023, as discussed further in Note 7.

The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 “ Fair Value Measurements ” below).

The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income.

Interest expense related to these financial instruments is included in the changes in fair value.

As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred.

The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were 13.55 % and nil for the years ended December 31, 2023 and 2022, respectively.

Derivative Liabilities

Derivative liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.

Research and Development Costs

2 unchanged sentences

Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development.

The provisions of the FASB ASC Topic 740, Income Taxes , addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.

In come Taxes

The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.

Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.

5 unchanged sentences

The Company determines if an arrangement is a lease at inception.

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

As the Company’s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.

The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.

Revenue Recognition

The Company’s revenue is generated from product sales within the United States.

The Company does not incur significant direct costs to obtain contracts with its customers.

Revenue from product sales is fully comprised of sales of ZTlido.

The Company’s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer.

The Company considers control to have transferred upon delivery because the customer has legal title to the product,

physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.

Revenue from product sales is comprised of sales of ZTlido and ELYXYB.

The Company’s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer.

The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.

Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant.

1 unchanged sentence

Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts.

Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company’s customer contract, customary industry practices and current government regulations.

Such variable

consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company’s customer contract, customary industry practices and current government regulations.

Rebates and Chargebacks

1 unchanged sentence

Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs.

Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider’s patient drug formulary.

Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.

2 unchanged sentences

The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.

Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company’s consolidated balance sheet.

Prompt Payment Discounts

3 unchanged sentences

The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.

The Company has determined such services received to date are not distinct from the Company’s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.

Product Returns

1 unchanged sentence

The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale.

The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.

The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized.

Co-Payment Assistance

1 unchanged sentence

The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.

Customer Concentration Risk

Prior to April 2, 2022, sales to the Company's sole distributor represented 100 % of net revenue.

On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies.

The distributor continued to provide traditional third-party logistics functions for the Company.

The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company’s total revenue.

These customers accounted for 83 % of the Company’s revenue for the year ended December 31, 2022, individually ranging between 19 % to 24 % .

As of December 31, 2022, these customers represented 90 % of the Company’s outstanding accounts receivable, individually ranging between 24 % to 36 % .

Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu.

This exposes the Company to concentration of customer and supplier risk.

The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020 .

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation –

Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services.

Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant) or non-employee’s vesting period.

The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services.

The Company accounts for forfeitures as incurred.

For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior.

term of the option and its ordinary vesting period since the Company does not have historic exercise behavior.

Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available.

1 unchanged sentence

Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.

The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.

Accordingly, the Company has determined that it operates its business as a single reportable segment.

Treasury Stock

The Company uses the cost method to account for repurchases of its stock.

In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares.

Net Loss per Share

4 unchanged sentences

As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.

Recent Accounting Pronouncements

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805):

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606.

ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted.

The Company is evaluating the impact the standard will have on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

In October 2021, FASB issued Accounting Standards Updates (“ASU”) 2021-08, Business Combinations (Topic 805):

Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) , which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606.

ASU 2021-08 is effective for fiscal years beginning after December 15, 2022.

ASU 2021-08 should be applied prospectively to business combinations occurring on or after the adoption date.

The Company adopted this guidance as of January 1, 2023 and the adoption did not have a material impact on the Company’s consolidated financial statements.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820):

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value.

Recognizing such a restriction as a separate unit of account is also not permitted.

ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted.

The Company elected to early adopt this guidance as of January 1, 2023 and the adoption did not have a material impact on the Company’s consolidated financial statements.

Liquidity and Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

Management has assessed the Company’s ability to continue as a going concern for at least one year after the date the financial statements are issued.

On March 18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3).

The Company anticipates the cash needed for the development of Semnur’s primary product candidate in development, SP-102, as well in the development of SP-103, will be in excess of the Company’s cash available within one year after the date these consolidated financial statements are issued.

Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements.

On May 12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the SP-104 Assets (see Note 3).

SP-104 has not been approved for commercialization and, as such, no revenues have been generated to date by the asset.

The Company will be responsible for funding all development and commercialization efforts.

On June 14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3).

The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses.

The Company anticipates incurring costs related to the commercial launch and marketing of GLOPERBA.

On September 12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement (see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company.

In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7).

In August 2022 and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $ 41.4 million .

Pursuant to Amendment No.

4 (see Note 7), a principal balance of $ 28.0 million was forgiven by the Scilex Pharma Note Purchasers (see Note 7) upon the Company’s exercise of the Early Paydown Provision.

The Company funded the principal payments with cash-on hand and $ 34.0 million received from Sorrento on September 28, 2022 (see Note 7).

As of December 31, 2022 , the Company’s negative working capital was $ 15.2 million , including cash and cash equivalents of approximately $ 2.2 million .

During the year ended December 31, 2022, the Company had operating losses of $ 50.6 million and cash flows used for operations o f $ 21.3 million .

The Company had an accumulated deficit of approximate ly $ 375.9 million as of December 31, 2022.

Management has assessed the Company’s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements.

On November 17, 2022, the Company entered into a standby equity purchase agreement (the “Original Purchase Agreement”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”).

On February 8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the “A&R Yorkville Purchase Agreement”), amending, restating and superseding the Original Purchase Agreement.

On January 8, 2023, the Company entered into a standby equity purchase agreement (the “B.

Riley Purchase Agreement” and together with A&R Yorkville Purchase Agreement, the “Standby Equity Purchase Agreements”) with B.

Principal Capital II, LLC (“B.

Pursuant to each of the Standby Equity Purchase Agreements, the Company has the right, but not the obligation, to sell to each of Yorkville and B.

Riley up to $ 500.0 million of shares of the Company’s common stock, par value $ 0.0001 per share (the “Common Stock”) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9.

On, and effective as of, February 16, 2024, the Company and B.

Riley mutually agreed to terminate the B.

Riley Purchase Agreement.

As consideration for Yorkville’s and B.

Riley’s respective commitment to purchase shares of Common Stock at the Company’s direction, the Company issued 250,000 commitment shares to each of Yorkville (the “Yorkville Commitment Shares”) and B.

Riley (the “B.

Riley Commitment Shares”).

On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the “Yorkville SPA”), pursuant to which the Company would issue and sell to Yorkville convertible debentures in an aggregate principal amount of up to $ 25.0 million (the “Convertible Debentures”).

As of December 31, 2023, Convertible Debentures in the principal amount of $ 25.0 million (for net cash proceeds of $ 24.0 million ) were issued and sold pursuant to the Yorkville SPA, which is discussed further in Note 7.

On June 27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the “eCapital Credit Agreement”) with eCapital Healthcare Corp.

(the “Lender”), pursuant to which the Lender shall make available loans (the “Revolving Facility”) in an aggregate principal amount of up to $ 30.0 million (the “Facility Cap”).

The proceeds of the Revolving Facility will be used for (i) transaction fees incurred in connection with the eCapital Credit Agreement, (ii) working capital needs of Scilex Pharma and (iii) other uses not prohibited under the eCapital Credit Agreement.

As of December 31, 2023, the Company has an outstanding balance of $ 17.0 million under the Revolving Facility.

See Note 7 for additional discussion of the terms of the eCapital Credit Agreement.

On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B.

Riley Securities, Inc., Cantor Fitzgerald & Co.

Wainwright & Co., LLC (the “Sales Agents”).

Pursuant to the ATM Sales Agreement, the Company may offer and sell (the “Offering”) shares of Common Stock up to $ 170,000,000 (the "ATM Shares"), through or to the Sales Agents as part of the Offering.

The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers thereunder at any time.

The Offering will terminate upon (i) the election of the Sales Agents upon the occurrence of certain adverse events, (ii) three business days’ advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii) the sale of all $ 170,000,000 of shares of Common Stock thereunder.

As of December 31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement.

As of December 31, 2023, the Company’s negative working capital was $ 203.6 million , including cash and cash equivalents of approximately $ 3.9 million .

During the year ended December 31, 2023, the Company had operating losses of $ 105.4 million and cash flows used for operations of $ 20.7 million .

The Company had an accumulated deficit of $ 490.2 million as of December 31, 2023.

The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions.

The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd.

(“Yorkville”) on November 17, 2022 (as amended and restated on February 8, 2023), and a Standby Equity Purchase Agreement with B.

Riley Principal Capital II, LLC (“B.

Riley”) on January 8, 2023 whereby the Company has the right, but not the obligation, to sell to Yorkville and B.

Riley up to $ 500.0 million each of shares of its Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14).

The Company’s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company’s marketing of ZTlido.

Should the Company’s sales of ZTlido not materialize at the expected rate contemplated in the Company’s business plan, due to the COVID-19 pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103, and SP-104, and other discretionary costs.

Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company’s control.

As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued.

As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued.

The Company’s plans are also dependent upon the success of future sales of ZTlido and ELYXYB, among which ELYXYB is still in the early stages of commercialization, and the future commercialization of GLOPERBA.

SP-104 Acquisition

On May 12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the “Bill of Sale”), with Sorrento.

Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento’s Delayed Burst Release Low Dose Naltrexone (“DBR-LDN”) asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the “SP-104 Assets”).

These assets had previously been acquired by Sorrento from Aardvark

Therapeutics, Inc.

(“Aardvark”) in April 2021 pursuant to an asset purchase agreement (the “Aardvark Asset Purchase Agreement”).

Pursuant to the Bill of Sale, the Company assumed all of Sorrento’s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the “SP-104 Acquisition”).

As consideration for the SP-104 Acquisition, the Company issued a promissory note in the aggregate principal amount of $ 5.0 million to Sorrento (the “2022 Promissory Note”).

Upon issuance of the note, the Company recorded a related party note payable of $ 4.1 million , net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company.

The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66 % simple interest per annum and (b) the maximum interest rate permitted under law.

The 2022 Promissory Note is payable in cash, shares of the Company’s common stock or any combination thereof, at the Company’s sole discretion, and may be prepaid in whole or in part at any time without penalty.

On November 10, 2022, the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12).

As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $ 3,000,000 , upon initial approval by the FDA of a new drug application for the SP-104 Assets (which amount may be paid in shares of the Company’s common stock or cash, in the Company’s sole discretion) (the “Development Milestone Payment”) and (ii) $ 20,000,000 , in cash, upon achievement of certain net sales by the Company of a commercial product that uses the SP-104 Assets (the “Sales Milestone Payment”).

In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the “SP-104 Assets”).

Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc.

(“Aardvark”) (i) $ 3.0 million upon initial approval by the FDA of a new drug application for the SP-104 Assets (which amount may be paid in shares of Common Stock or cash, in the Company’s sole discretion) (the “Development Milestone Payment”) and (ii) $ 20.0 million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the SP-104 Assets (the “Sales Milestone Payment”).

The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the SP-104 Assets.

The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, SP-104 Assets.

The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, Derivatives and Hedging , and will not be recognized until the contingencies are realized in accordance with the Company’s accounting policy for contingent consideration in an asset acquisition.

The Development Milestone Payment represents a liability within the scope of ASC Topic 480, Distinguishing Liabilities from Equity , which will be measured at fair value each reporting period.

As of December 31, 2022, the contingent consideration of $ 0.2 million associated with Development Milestones Payment was recognized under other long-term liabilities.

The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized.

The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period.

As of December 31, 2023 and December 31, 2022, the contingent consideration associated with the Development Milestone Payment was $ 0.2 million , recorded in the other long-term liabilities.

GLOPERBA License Agreement

On June 14, 2022, the Company entered into a license agreement (the “Romeg License Agreement”) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (“Romeg”).

Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein (with such license to know-how being exclusive for the limited purposes specified therein) to (i) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the “Initial Licensed Product”

or “GLOPERBA”) in the United States of America (including its territories) (the “Territory”), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the “Licensed Products”) and commercialize any such products and (iii) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory;

and (2) an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory.

In June 2022, the Company entered into a license agreement (the “Romeg License Agreement”) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (“Romeg”).

Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a) a transferable license, with a right to sublicense, to (i) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the “Initial Licensed Product” or “GLOPERBA”) in the United States (including its territories) (the “GLOPERBA Territory”), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the “Licensed Products”) and commercialize any such products and (iii) manufacture Licensed Products anywhere in the world, solely for commercialization in the GLOPERBA Territory;

and (b) an exclusive, transferable license, with a right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the GLOPERBA Territory.

The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020.

As consideration for the license under the Romeg License Agreement, the Company paid Romeg an up-front license fee of $ 2.0 million , and has agreed to pay Romeg (a) upon the Company’s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $ 13.0 million, (b) certain royalties in the mid-single digit to low-double digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c) minimum quarterly royalty payments totaling $ 7.1 million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.

The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product.

In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $ 5.7 million , which is comprised of the upfront license fee of $ 2.0 million and a deferred consideration of $ 3.7 million that is the present value of the future minimum royalty payments and immaterial transaction costs.

The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized.

No contingent consideration was recognized as a liability or included in the fair value of the assets as of December 31, 2022.

The Company determined the useful life of the intangible asset to be 15 years, which approximates the life of the licensed patents covering the Initial Licensed Product.

As consideration for the license under the Romeg License Agreement, the Company paid Romeg an up-front license fee of $ 2.0 million , and has agreed to pay Romeg (a) upon the Company’s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $ 13.0 million , (b) certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by the Company during the applicable royalty term under the Romeg License Agreement, and (c) minimum quarterly royalty payments totaling $ 7.1 million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last-to-expire of the licensed patents covering the Licensed Products in the GLOPERBA Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.

In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $ 5.7 million , which is comprised of the upfront license fee of $ 2.0 million and deferred consideration of $ 3.7 million that is the present value of the future minimum royalty payments and immaterial transaction costs.

No contingent consideration was recognized as a liability or included in the fair value of the assets as of December 31, 2023 or December 31, 2022.

ELYXYB Acquisition

On February 12, 2023, the Company entered into an asset purchase agreement (the “ELYXYB APA”) with BioDelivery Sciences International, Inc.

(“BDSI”) and Collegium Pharmaceutical, Inc.

(“Collegium”, and together with BDSI, the “Sellers”) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the “ELYXYB Territory”).

As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.

Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), dated August 3, 2021 (the “DRL APA”), including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory.

No cash consideration was or will be payable to the Sellers for such acquisition;

however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties.

The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory.

In April 2023, the Company launched ELYXYB in the U.S.

As of December 31, 2023, the Company had ending balances of accrued royalty payables of $ 5.0 thousand .

As of December 31, 2023 , no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.

Fair Value Measurements

The following table presents the Company’s financial assets and liabilities that are measured at fair value (in thousands):

Fair value measurements at December 31, 2022

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):

December 31, 2023

Quoted Prices

1 unchanged sentence

Significant Unobservable Inputs (Level 3)

Cash and cash equivalents

Total assets measured at fair value

Convertible Debentures

Derivative liabilities

1 unchanged sentence

Total liabilities measured at fair value

Fair value measurements at December 31, 2021

December 31, 2022

Quoted Prices

1 unchanged sentence

Inputs (Level 3)

Cash and cash equivalents

Total assets measured at fair value

Derivative liabilities

Other long-term liabilities

Total liabilities measured at fair value

Cash and cash equivalents

The Company’s financial assets carried at fair value are comprised of cash and cash equivalents.

Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable.

These assets are valued using inputs observable in active markets for identical securities.

The Oramed Note

In September 2023, the Company issued a senior secured promissory note to Oramed Pharmaceuticals Inc.

(“Oramed”) in the principal amount of $ 101.9 million (the “Oramed Note”) (see Note 7).

The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the consolidated statements of operations.

The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level 3 inputs.

This methodology discounts the interest and principal payments using a risk-adjusted discount rate.

The fair value as of December 31, 2023 was determined to be $ 104.1 million by applying a discount

rate of 13.05 % .

For the year ended December 31, 2023, the Company recorded $ 2.8 million in change in fair value of the Oramed Note.

Convertible Debentures

In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $ 25.0 million (see Note 7).

The Convertible Debentures are measured at fair value on a recurring basis using Level 3 inputs.

The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations.

Interest expense related to the Convertible Debentures is included in the changes in fair value.

For the year ended December 31, 2023, the Company recorded $ 4.4 million in change in fair value of the Convertible Debentures.

A summary of inputs used in valuing the Convertible Debentures is as follows:

Risk -Free Rate

Corporate Bond Yield

Coupon Interest Rate

Dividend Yield

Conversion Price

Derivative Liabilities

The Company recorded a gain of $ 8.3 million , loss of $ 0.3 million, and gain of $ 0.8 million on derivative liabilities for the years ended December 31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note 7) and Private Warrants.

The Company recorded a gain of $ 0.5 million and $ 8.3 million and a loss of $ 0.3 million for the years ended December 31, 2023, 2022 and 2021, respectively, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination and compound derivative liabilities associated with the senior secured notes issued by Scilex Pharma in September 2018 (the “Scilex Pharma Notes”), respectively.

The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $ 30.4 million immediately after entry into Amendment No.

4 (see Note 7) associated with the Scilex Pharma Notes on June 2, 2022.

4 to the Scilex Pharma Notes on June 2, 2022 (“Amendment No.

The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.

Significant Level 3 assumptions used in the measurement included a 6.1 % risk adjusted net sales forecast and an effective debt yield of 21.5 %.

The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December 31, 2022.

At the closing of the Business Combination, the Company assumed a derivative warrant liability of $ 2.5 million related to Private Warrants (See Note 8).

The fair value of derivative warrant liability related to Private Warrants was $ 1.2 million as of December 31, 2022.

The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2022:

Ending Balance at December 31, 2019

Loan derivative liability

Re-measurement of fair value

Ending Balance at December 31, 2020

The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December 31, 2022.

At the closing of the Business Combination in November 2022, the Company assumed a derivative warrant liability of $ 2.5 million related to the Private Warrants.

As of December 31, 2023, 3,613,383 Private Warrants were outstanding, and the fair value of derivative warrant liability related to the Private Warrants was $ 1.5 million .

The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December 31, 2023, 2022 and 2021 (in thousands):

Ending Balance as of December 31, 2020

Re-measurement of fair value

Balance at December 31, 2021

Ending Balance as of December 31, 2021

Private warrant liability acquired as part of the Business Combination

1 unchanged sentence

Change in fair value measurement

Balance at December 31, 2022

Ending Balance as of December 31, 2022

Change in fair value measurement

Forfeiture of Private Warrants

Ending Balance as of December 31, 2023

Warrant Liability Measurement

1 unchanged sentence

The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock.

The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants.

The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9 ).

A summary of the inputs used in valuing the derivative warrant liabilities is as follows:

December 31, 2022

November 10, 2022

Exercise price

3 unchanged sentences

Call option value

Contingent Consideration

The Development Milestone Payment represents a liability under the scope of ASC Topic 480, Distinguishing Liabilities from Equity , as it pertains to a potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock.

Contingent Consideration Related to SP-104 Acquisition

The Development Milestone Payment related to the SP-104 Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement.

Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $ 3.0 million in cash or shares of Common Stock, at the discretion of the Company.

The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash flow method.

Significant Level 3 assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 10.0 % .

As of December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $ 0.2 million .

The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method.

Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of 10.2 % .

As of December 31, 2023 and December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $ 0.2 million .

There were no transfers between fair value measurement levels during the years ended December 31, 2023, 2022 and 2021 .

Balance Sheet Components

Property and Equipment, Net

Property and equipment consisted of the following as of December 31, 2022 and 2021 (in thousands):

Computers & equipment

Leasehold improvements

Property and equipment, net, consists of the following (in thousands):

Construction in progress

Computers and equipment

Leasehold improvements

Property and equipment, gross

1 unchanged sentence

Property and equipment, net

Depreciation expense for each of the years ended December 31, 2022, 2021, and 2020 was $ 40 thousand, $ 39 thousand, and $ 40 thousand, respectively.

The Company recognized depreciation expense of $ 40.0 thousand, $ 40.0 thousand and $ 39.0 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.

Accrued Expenses

Accrued expenses consists of the following (in thousands):

Accrued professional service fees

Accrued sales and marketing costs

Accrued research and development costs

Accrued tax payable

Accrued others

Accrued expenses

Goodwill and Intangible Assets

As of December 31, 2022 and December 31, 2021, the Company had recorded goodwill of $ 13.5 million .

The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2022.

Based upon the results of the qualitative testing, the Company concluded that it is more-likely-than-not that the fair value of the Company’s goodwill was in excess of the carrying value and therefore performing the first step of the two-step

impairment test was unnecessary.

The conclusion has not changed as of December 31, 2022 and no goodwill impairment was recognized for the years ended December 31, 2022 and 2021.

The Company’s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce.

As of December 31, 2023 and 2022, the Company had recorded goodwill of $ 13.5 million .

No goodwill impairment was recognized for the years ended December 31, 2023, 2022 and 2021.

Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives.

A summary of the Company’s identifiable intangible assets as of December 31, 2022 and December 31, 2021 is as follows (in thousands):

A summary of the Company’s identifiable intangible assets as of December 31, 2023 and December 31, 2022 is as follows (in thousands):

December 31, 2023

13 unchanged sentences

Acquired technology

Acquired licenses

Assembled workforce

Total intangible assets

On June 14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3).

The Company determined the acquisition of licenses to be an asset acquisition.

The fair value of consideration transferred of $ 5.7 million was assigned to acquired licenses with an amortization period of approximately 15 years.

As of December 31, 2023, the weighted average remaining life for identifiable intangible assets was 9.4 years.

Aggregate amortization expense was $ 3.9 million , $ 3.7 million, an d $ 3.7 million for the years ended December 31, 2022, 2021, and 2020, respectively.

Aggregate amortization expense was $ 4.1 million, $ 3.9 million and $ 3.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Patent rights and acquired technology are amortized over a 15-year period.

Assembled workforce is amortized over a 5-year period.

Estimated future amortization expense related to intangible assets at December 31, 2022 is as follows (in thousands):

Year Ended December 31,

2018 Purchase Agreements and Indenture

On September 7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the “2018 Purchase Agreements”) with certain investors (collectively, the “Scilex Pharma Note Purchasers”).

Pursuant to the 2018 Purchase Agreements, on September 7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $ 224.0 million (the “Scilex Pharma Notes”) for an aggregate purchase price of $ 140.0 million (the “Offering”).

The Scilex Pharma Notes were governed by an indenture (as amended, the “Indenture”) with Scilex Pharma, as issuer, U.S.

Bank National Association, a national banking association, as trustee (the “Trustee”) and collateral agent (the “Collateral Agent”), and Sorrento, as guarantor.

Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the “Guarantee”).

The principal amount of the Scilex Pharma Notes increased by $ 28.0 million on February 15, 2022 as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 not equal or exceeding $ 481.0 million.

As a result, the Company recorded the increase of $ 28.0 million in principal and non-operating expense at December 31, 2021.

Effective February 14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 were less than a specified sales threshold for such period.

As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $ 35.0 million in a single lump-sum amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $ 10.0 million.

In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $ 20.0 million.

On June 2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.

4 to Indenture (the “Amendment No.

4”) with U.S.

Bank Trust Company, National Association (as successor in interest to U.S.

Bank National Association) and the Scilex Note Purchasers.

Pursuant to Amendment No.

4, (1) on June 3, 2022, Scilex Pharma repurchased approximately $ 41.4 million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100 % of the principal amount thereof, (2) the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $ 41.4 million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $ 28.0 million of the aggregate principal amount of the Scilex Pharma Notes (the “Early Paydown Provision”), (3) the minimum cash requirement under the Indenture was reduced to $ 5.0 million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $ 25.0 million to up to $ 50.0 million.

The Company funded the repurchase with cash-on-hand and $ 15.0 million received from Sorrento on June 2, 2022.

The Company concluded that the Amendment No.

4 was a troubled debt restructuring for accounting purposes.

The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.

4, and accordingly, no gain was recognized in the quarter ended June 30, 2022.

Due to a decrease of $ 30.4 million in the fair value of the Scilex Notes Derivative caused by the Amendment No.

4, the carrying value of the Scilex Notes was increased by $ 30.4 million.

In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes.

In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $ 1.7 million and $ 39.7 million , respectively.

Pursuant to Amendment No.

4, $ 28.0 million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022.

The Company funded the repurchase with cash-on-hand and $ 34.0 million received from Sorrento on September 28, 2022.

The Company recorded a gain on debt extinguishment of $ 28.6 million as a result of the extinguishment.

Borrowings of the Scilex Notes consisted of the following (in thousands):

December 31, 2021

Unamortized debt discount

Unamortized debt issuance costs

Carrying value

Current portion

Long term portion

Estimated fair value

The Company made principal payments of $ 106.0 million , $ 45.9 million, and $ 69.8 million during the years ended December 31, 2022, 2021, and 2020, respectively.

The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $ 3.1 million , $ 7.9 million and $ 10.7 million, respectively.

The Company recorded a gain on debt extinguishment of $ 28.6 million , a loss on debt extinguishment of $ 12.5 million, and no gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended December 31, 2022, 2021, and 2020 , respectively.

Related Party Notes Payable

On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12).

On March 18, 2019, the Company entered into a note payable with Sorrento (see Note 12).

On February 14, 2022, Sorrento paid to Scilex Pharma $ 35.0 million in a single lump-sum amount as a subordinated loan (see Note 12).

On May 12, 2022, the Company issued Sorrento a promissory note of $ 5.0 million in exchange for the SP-104 Assets (see Note 3).

On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12).

2020 Revolving Credit Facility

On December 14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the “Credit Agreement”) with CNH Finance Fund I, L.P.

(“CNH”) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $ 10.0 million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility.

Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75 %.

All indebtedness incurred and outstanding will be due and payable in full on January 1, 2024;

unless the Credit Agreement is earlier terminated.

As of December 31, 2021 , the outstanding balance was $ 8.8 million.

On February 16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022.

Upon termination, all principal balances and interest accrued were settled.

Stockholders’

The consolidated statement of stockholders’

equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1.

The balances as of December 31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional paid-in-capital) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.

Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized 740,000,000 shares of Common Stock with a par value of $ 0.0001 .

As of December 31, 2022 and December 31, 2021, there were 141,348,856 shares issued and 132,858,484 of Common Stock outstanding, respectively.

In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio.

The Company has retroactively adjusted shares issued and outstanding prior to November 10, 2022 to give effect to the Common Stock Exchange Ratio to determine the number of shares of Common Stock into which they were converted.

The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders.

Common stockholders are entitled to receive dividends whenever funds are legally available and when declared by the Company's board of directors.

No dividends have been declared as of December 31, 2022.The Stockholder Agreement, dated as of September 12, 2022, between Vickers and Sorrento (the “Stockholder Agreement”), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento.

Such actions include, among other things, the payment of dividends on shares of the Common Stock.

Liquidation Rights

Subject to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or winding-up, holders of Common Stock are entitled to share equally in the assets available for distribution after payment of all creditors.

Estimated future amortization expense related to intangible assets as of December 31, 2023 is as follows (in thousands):

Convertible Debentures

On March 21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $ 25.0 million.

The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96 % of the applicable principal amount in three tranches as follows:

(i) $ 10.0 million upon the signing of the Yorkville SPA, which was funded on March 21, 2023;

(ii) $ 7.5 million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the “Securities Act”), which was funded on April 11, 2023 ;

and (iii) $ 7.5 million at the time such registration statement was declared effective by the SEC, which was funded on April 20, 2023 .

The Convertible Debentures bear interest at an annual rate of 7.00 % and were initially set to mature on December 21, 2023 .

On October 11, 2023, the Company and Yorkville amended the Convertible Debentures.

The Default Conversion Price (as defined therein) was originally set not to fall below $ 2.00 per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $ 0.50 per share.

The maturity date of the Convertible Debentures was also extended from December 21, 2023 to March 15, 2024 .

The outstanding principal amount is to be repaid in equal installments that are due every 30 days beginning on May 20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville.

The Convertible Debentures provide a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest may be converted into shares of Common Stock, at a conversion price of $ 8.00 per share at the option of the holder of the Convertible Debentures.

The Company has the option to repay either (i) in cash, with premium equal to 5 % in respect of the principal amount of such payment, or (ii) by submitting a notice for an advance under the A&R Yorkville Purchase Agreement , or a series of advances thereunder, or any combination of (i) or (ii) as determined by the Company.

In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.

The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures;

provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice.

The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10 % of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.

The Company has elected the fair value option for the Convertible Debentures and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period.

Pursuant to the Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $ 15.0 million in April 2023 for $ 14.4 million in net cash proceeds.

In April 2023, Yorkville elected to convert $ 5.0 million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of 632,431 shares of Common Stock at a conversion price of $ 8.00 per share and reducing the outstanding Convertible Debentures fair value balance by $ 4.4 million .

The Company repaid $ 15.6 million of the Convertible Debentures during the year ended December 31, 2023 .

Interest expense related to the Convertible Debentures and included in the changes in fair value was $ 0.7 million for the year ended December 31, 2023.

The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands):

Beginning Balance as of January 1, 2023

Issuance of Convertible Debentures

Repayment of Convertible Debentures

Change in fair value of Convertible Debentures

Conversion of Convertible Debentures into Common Stock

Ending Balance as of December 31, 2023

Revolving Facility

On June 27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $ 30.0 million .

The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $ 250,000 at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds 95 % of the then-existing Facility Cap.

The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and 85 % of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion.

Under the terms of the eCapital Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.5 % , based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July 1, 2023.

The eCapital Credit Agreement provides for an early termination fee of 0.5 % of the Facility Cap if Scilex Pharma voluntarily prepays and terminates in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility.

In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma’s collections and eCapital Credit Agreement funding accounts, which permit the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account.

All indebtedness incurred and outstanding under the eCapital Credit Agreement will be due and payable in full on July 1, 2026, unless the eCapital Credit Agreement is earlier terminated.

The eCapital Credit Agreement contains a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $ 1.0 million at all times.

Scilex Pharma’s obligations under the eCapital Credit Agreement are secured by a continuing security interest in Scilex Pharma’s accounts receivable, arising from customers in the ordinary course of business.

The eCapital Credit Agreement contains customary events of default and also provides that an event of default includes a change of control of Scilex Pharma and the failure by the Company to issue at least $ 75.0 million of debt or equity by September 30, 2023, which condition was satisfied by the issuance of the Oramed Note.

As of December 31, 2023, Scilex Pharma has an outstanding balance of $ 17.0 million under the Revolving Facility, which is classified as a long-term liability in the consolidated balance sheet.

On September 21, 2023, Scilex Pharma signed a subordination agreement (the “Subordination Agreement”) with the Lender and Acquiom Agency Services LLC (the “Agent”).

Pursuant to the Subordination Agreement, the rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein).

The ABL Priority Collateral consists of all of the Company’s properties identified in the description of collateral in the UCC-1 Financing Statement filed with the Delaware Secretary of State on June 27, 2023.

The Agent’s rights and interests under that certain Subsidiary Guarantee, dated as of September 21, 2023, entered into by us and each of our subsidiaries with Oramed and the Agent (the “Subsidiary Guarantee”), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral.

The Subordination Agreement also includes other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $ 30.0 million.

The Oramed Note

On September 21, 2023, the Company entered into a securities purchase agreement with Oramed (the “Scilex-Oramed SPA”), pursuant to which the Company issued the Oramed Note.

The Oramed Note, which has a principal amount of $ 101.9 million , matures on March 21, 2025 .

It is payable in six principal installments, with the first installment of $ 5.0 million payable on December 21, 2023 , the second installment in the principal amount of $ 15.0 million payable on March 21, 2024 , the next three installments each in the principal amount of $ 20.0 million payable on each of June 21, 2024 , September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025 .

Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) greater of (x) 4 % and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5 %, payable in-kind on a monthly basis.

If the outstanding principal has not been fully repaid by March 21, 2024, an exit fee of approximately $ 3.1 million becomes due upon repayment.

Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50 % of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15 % or (ii) the maximum rate permitted under applicable law.

Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50 % of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date.

If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125 % of the principal amount (together with 100 % of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note).

The Oramed Note contains mandatory prepayment provisions requiring use of 70 % of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).

The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note.

The Company was in compliance with all of the covenants as of December 31, 2023.

In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the “Guarantors”) entered into a security agreement (the “Security Agreement”) with Oramed (together with its successors and permitted assigns, the “Holder”) and the Agent, which acts as the collateral agent for the holders of the Oramed Note.

Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors.

This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note.

The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement.

At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation.

In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period.

As of December 31, 2023, the fair value of the Oramed Note was $ 104.1 million , which is classified as a current liability in the consolidated balance sheet.

The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands):

Beginning Balance as of January 1, 2023

Issuance of Oramed Note

Change in fair value of Oramed Note

Repayment of Oramed Note

Ending Balance as of December 31, 2023

Junior DIP Facility and Sorrento Stock Purchase Agreement

Junior DIP Facility

In July 2023, the Company entered into an agreement to provide Sorrento with a non-amortizing super-priority junior secured term loan facility (“Junior DIP Facility”) in an aggregate principal amount of $ 20.0 million (the “Junior DIP Loan Agreement”), which was funded in the same month.

The Junior DIP Facility bears interest at a per annum rate of 12.0 % payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement).

Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to 2.00 % of the aggregate principal amount of the Junior DIP Facility.

The Junior DIP Facility was to mature on the earliest of:

(i) September 30, 2023;

(ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento;

(iii) the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento;

(iv) the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement) ;

and (v) dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.

On September 21, 2023, Sorrento’s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below.

Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento.

Sorrento Stock Purchase Agreement

On September 21, 2023, the Company entered into a Stock Purchase Agreement with Sorrento (“Sorrento SPA”), pursuant to which the Company purchased from Sorrento (i) 60,068,585 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock, par value $ 0.0001 per share, of the Company (the “Preferred Stock”) and (iii) 1,386,617 Public Warrants and 3,104,000 Private Warrants (collectively, the “Purchased Securities”).

On the same day, the Company and Oramed entered into the Scilex-Oramed SPA.

The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento.

Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7 ), which replaced Sorrento’s outstanding obligations to Oramed, warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock (the “Closing Penny Warrant”) with an exercise price of $ 0.01 per share and restrictions on exercisability, and warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the “Subsequent Penny Warrants” and together with the Closing Penny Warrant, the “Penny Warrants”), each with an exercise price of $ 0.01 per share and each with restrictions on exercisability.

Additionally, the Company agreed to transfer to Oramed 4,000,000 SPAC Warrants, which were acquired by the Company under the Sorrento SPA.

There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above.

The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $ 10.0 million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $ 12.3 million .

The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants based on their relative fair values as of September 21, 2023.

Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities:

(a) Scilex DRE Holdings LLC (“Holdco”), a single purpose entity

that is the Company’s direct wholly owned subsidiary and (b) Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company’s indirect wholly owned subsidiary (“SCLX JV”), which was formed to hold the Purchased Securities.

Holdco was formed to hold all of the equity interests in SCLX JV.

Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7).

Preferred Stock

Upon the closing of the Business Combination, $ 290.6 million of all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (“Series A Preferred Shares”

or “Series A Preferred Stock”).

In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of

domesticated parent preferred shares (“New Scilex Preferred Stock”

or “Preferred Stock”) par value of $ 0.0001 per share, and 2) one-tenth of one domesticated parent common stock (“New Scilex Common Stock”

or “Common Stock”

and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the “Conversion”

or “Contribution”).

Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to 45,000,000 shares and a Certificate of Designation (“Certificate of Designation”) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares.

In connection with the closing of the Business Combination, the Company filed the Certificate of Designation and issued 29,057,097 shares of the Series A Preferred Stock to Sorrento.

As of December 31, 2022, there were 29,057,097 shares of Preferred Stock outstanding.

There were no Preferred Stock outstanding at December 31, 2021.

The Company’s Board of Directors have authority to issue such shares of Preferred Stock in one or more series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares.

Other than the Series A Preferred Stock issued to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred stock.

The holders of shares of Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote.

The holders of shares of Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote.

Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to the Board of Directors of the Company.

The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges, limitations and restrictions.

Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions.

Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock.

Liquidation Rights

Subject to the rights of the holders of parity shares (if any), in the event of our liquidation, dissolution or winding-up, holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets available for distribution after payment of all creditors.

Assumed Public Warrants and Private Warrants

Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the Company.

The warrants are exercisable on the later of (a) the completion of a Business Combination and (b) 12 months from the closing of Vickers's Initial Public Offering.

The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.

Each warrant entitles the holder to purchase one share of Common Stock for $ 11.50 per share.

If the reported last sale price of the Common Stock equals or exceeds $ 18.00 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $ 0.01 per warrant upon not less than 30 days’

prior written notice.

Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Preferred Stock .

The Preferred Stock is classified in equity and does not have any bifurcated features.

Therefore, the repurchase of the Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend.

The fair value of Preferred Stock as of the repurchase date of September 21, 2023 was $ 52.6 million .

The Company derecognized the carrying value of the Preferred Stock, with any excess amount allocated as the reduction in additional paid-in capital.

The Preferred Stock is currently held as collateral for the Oramed Note.

Treasury Stock

The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note.

In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity.

Penny Warrants

The Closing Penny Warrant will be exercisable upon the earliest of (i) March 14, 2025 , (ii) the date on which the Oramed Note has been repaid in full and (iii) the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date.

The Company issued four Subsequent Penny Warrants, each for 2,125,000 shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i) each of March 19, 2024 , June 17, 2024 , September 15, 2024 or December 14, 2024 (the “Subsequent Penny Warrant Vesting Date”) and (ii) the earliest of (A) March 14, 2025 , (B) the date on which the Oramed Note has been repaid in full and (C) the Management Sale Trigger Date (as defined therein), if any.

Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date;

provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full.

The exercise price of the Penny Warrants is $ 0.01 per share, subject to adjustments provided therein.

The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants;

provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares.

Oramed may exercise the Penny Warrants by means of a “cashless exercise.” The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant.

The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9 % of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the “Oramed Beneficial Ownership Limitation”);

provided, however, that upon 61 days’ prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation.

The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company’s own stock and meet the conditions to be classified in equity under FASB ASC 815, Derivatives and Hedging, including sufficient available shares for the Company to settle the exercise of the warrants in shares.

The Penny Warrants are recognized in additional paid-in capital in the Company’s consolidated balance sheets.

The fair value of Penny Warrants as of September 21, 2023, the date of issuance, was $ 10.4 million .

In December 2022, the Department of the Treasury and the Internal Revenue Service (the “IRS”) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments.

Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento.

The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December 31, 2023.

The Company has accrued $ 1.3 million of the excise tax liability, which is recorded as accrued expenses under current liabilities on the consolidated balance sheet.

The excise tax will be adjusted based on any new guidance that the IRS may release.

Stockholders’ Equity

SPAC Warrants

Upon the completion of the Business Combination, the Company assumed the SPAC Warrants.

Holders of the SPAC Warrants are entitled to acquire shares of Common Stock.

The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.

If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis.

The Company will not be required to net cash settle the warrants.

As of December 31, 2022, there are 6,899,988 Public Warrants outstanding.

In connection with the closing of the Business Combination, 3,104,000 Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (“Warrant Transfer Agreement”).

As of December 31, 2022, there are 4,104,000 Private Warrants outstanding, of which 3,104,000 Private Warrants are held by Sorrento and 1,000,000 Private Warrants are held by Sponsors.

Legacy Scilex Common Stock and Preferred Stock

Prior to the Business Combination, Legacy Scilex had the authority to issue 200,000,000 shares of common stock, par value $ 0.0001 per share and 20,000,000 shares of preferred stock, par value $ 0.0001 per share per the Certificate of Incorporation dated February 27, 2019.

The Certificate of Incorporation was amended and restated on March 4, 2019 (“First Amended Certificate of Incorporation”), in which Legacy Scilex had the authority to issue 350,000,000 shares of common stock, par value $ 0.0001 per share and 20,000,000 shares of preferred stock, par value $ 0.0001 per share.

The First Amended and Restated Certificate of Incorporation was amended and restated on November 10, 2022 (“Second Amended Certificate of Incorporation”).

As a result of the Second Amended Certificate of Incorporation, Legacy Scilex had the authority to issue 785,000,000 shares, consisting of 740,000,000 shares of common stock and 45,000,000 shares of preferred stock.

Immediately prior to the Conversion, there were 197,566,338 shares of Legacy Scilex Common Stock outstanding and 29,057,097 shares of Series A Preferred Stock, par value $ 0.0001 per share, of Legacy Scilex outstanding.

Yorkville Standby Equity Purchase Agreement

On November 17, 2022, the Company entered into a Standby Equity Purchase Agreement (the “Yorkville Purchase Agreement”) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to $ 500.0 million of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions.

Pursuant to the Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a “Yorkville Advance”) will be purchased at a price equal to 98 % of the lowest daily volume weighted

average price of the Common Stock for any trading day (“VWAP”) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a “Yorkville Advance Notice”).

As consideration for Yorkville's commitment to purchase shares of Common Stock at the Company’s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued 250,000 shares of Common Stock to Yorkville and paid $ 10.0 thousand in structuring fees.

The registration statement on Form S-1 (File No.

333-268607) related to the Yorkville Purchase Agreement was filed with the SEC on November 30, 2022 and was declared effective by the SEC on December 9, 2022.

As of December 31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement.

Refer to Note 14 “Subsequent Event”

below for a subsequent event related to the Yorkville Purchase Agreement.

Stock Incentive and Employee Benefit Plans

The consolidated statements of stockholders’

equity / (deficit) have been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1.

The balances as of December 31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.

The Company will not be required to net cash settle the SPAC Warrants.

The Public Warrants are equity-classified warrants and recognized in additional paid-in capital in the accompanying consolidated balance sheets.

The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4).

During the year ended December 31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8).

As of December 31, 2023 and 2022, there were 6,854,309 and 6,899,988 Public Warrants outstanding, respectively.

As of December 31, 2023 and 2022, there were 3,613,383 and 4,104,000 Private Warrants outstanding, respectively.

Preferred Stock

As of December 31, 2023 and 2022, there were 29,057,097 shares of Preferred Stock outstanding.

On September 21, 2023, the Preferred Stock was repurchased and derecognized for accounting purposes.

The Preferred Stock is currently held as collateral for the Oramed Note.

Treasury Stock

As of December 31, 2023, there were 60,068,585 shares of Treasury Stock.

A&R Yorkville Purchase Agreement

Pursuant to the A&R Yorkville Purchase Agreement, the Company has the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $ 500.0 million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the 36-month anniversary of the date on which the Company’s registration statement on Form S-1 registering such shares has been declared effective by the SEC.

Pursuant to the A&R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to 98 % of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m.

on the same day.

For purposes of the A&R Yorkville Purchase Agreement, “VWAP” means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P.

through its “AQR” function.

Pursuant to the terms of the Original Purchase Agreement, the Company filed a registration statement on Form S-1 (File No.

333-268607) (as it may be amended or supplemented from time to time, the “Yorkville Registration Statement”) related to the Original Purchase Agreement with the SEC on November 30, 2022 (following the execution of the Original Purchase Agreement).

The Yorkville Registration Statement was initially declared effective by the SEC on December 9, 2022.

In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville 250,000 shares of Common Stock.

During the year ended December 31, 2023, the Company sold 11,552,074 shares of Common Stock pursuant to the A&R Yorkville Purchase Agreement for aggregate net proceeds of $ 32.3 million .

Riley Purchase Agreement

Pursuant to the B.

Riley Purchase Agreement, the Company has the right, but not the obligation, to sell to B.

Riley up to $ 500.0 million of shares of Common Stock, subject to certain limitations and conditions set forth therein, from time to time at the Company’s sole and absolute discretion, during the term of the B.

Riley Purchase Agreement.

The Company’s right to sell shares of Common Stock pursuant to the B.

Riley Purchase Agreement shall end on the first day of the month following the 36-month anniversary of the date on which the B.

Riley Registration Statement (as defined below) was initially declared effective by the SEC.

Pursuant to the terms of the B.

Riley Purchase Agreement, the Company filed a registration statement on Form S-1 (File No.

333-269205) (as it may be amended or supplemented from time to time, the “B.

Riley Registration Statement”) related to the B.

Riley Purchase Agreement with the SEC on January 12, 2023 (following the execution of the B.

Riley Purchase Agreement).

Riley Registration Statement was initially declared effective by the SEC on January 20, 2023.

The shares of Common Stock, if any, that the Company elects to sell to B.

Riley pursuant to an advance under the B.

Riley Purchase Agreement will be purchased at a price equal to 98 % of the VWAP (as defined in such agreement) during the pricing period prescribed therein.

In connection with the execution of the B.

Riley Purchase Agreement, the Company issued to B.

Riley 250,000 shares of Common Stock.

During the year ended December 31, 2023, the Company sold an aggregate of 1,414,554 shares of Common Stock for aggregate net proceeds of $ 3.2 million .

On, and effective as of, February 16, 2024, the Company and B.

Riley mutually agreed to terminate the B.

Riley Purchase Agreement.

Stock Issued under Settlement Agreement with Hudson Bay Parties

In August 2023, the Company, along with Hudson Bay Capital Management LP (“Hudson Bay”), Cove Lane Onshore Fund, LLC (“Cove Lane”), and HBC Investments LLC (“HBC” and collectively, the “Hudson Bay Parties”), entered into several agreements.

Under these agreements, the Company agreed to issue and sell up to $ 118.6 million in securities and warrants to the Hudson Bay Parties.

However, on September 15, 2023, a settlement agreement was reached and released all claims related to the previous agreements.

The Company acknowledged payments of $ 8.65 million made to the Hudson Bay Parties as properly earned.

To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $ 0.3 million and $ 0.5 million , respectively.

This resulted in the issuance of an aggregate of 474,683 shares of Common Stock on September 25, 2023.

At-the-Market Sales Agreement

On December 22, 2023, the Company entered into a Sales Agreement (the “ATM Sales Agreement”) with B.

Riley Securities, Inc., Cantor Fitzgerald & Co.

Wainwright & Co., LLC (the “Sales Agents”).

Pursuant to the ATM Sales Agreement, the Company may offer and sell (the “Offering”) shares of Common Stock up to $ 170,000,000 (the “ATM Shares”), through or to the Sales Agents.

The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time.

The ATM Shares offered and sold in the Offering will be issued pursuant to the Company’s shelf registration statement on Form S-3 (the “Shelf S-3 Registration Statement”), filed with the SEC on December 22, 2023, and declared effective by the SEC on January 11, 2024.

The ATM Shares may be offered only by means of a prospectus forming a part of the Shelf S-3 Registration Statement.

The Sales Agents are entitled to a commission equal to 3.0 % of the gross proceeds from each sale of shares of Common Stock.

The Company will also reimburse the Sales Agents for certain expenses and has agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the Securities Act.

As of December 31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement.

Stock Incentive and Employee Benefit Plan

2017 Scilex Pharmaceuticals Inc.

Equity Incentive Plan

In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc.

2017 Equity Incentive Plan (the “Scilex Pharma 2017 Plan”).

The Scilex Pharma 2017 Plan reserved 24.0 million shares of Scilex Pharma common stock.

Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.

The Scilex Pharma 2017 Plan was amended and restated on July 5, 2018.

In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma’s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire Legacy Scilex Common Stock.

In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc.

Equity Incentive Plan (the “Scilex Pharma 2017 Plan”).

In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated.

Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan.

Scilex Holding Company 2019 Stock Option Plan

The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the “2019 Stock Option Plan”

or “Prior Plan”) on May 28, 2019.

The 2019 Stock Option Plan was approved by the Company’s stockholders on June 7, 2019.

As of December 31, 2019, 30.0 million shares of Scilex Common Stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan.

Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.

Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further awards were granted under the 2019 Stock Option Plan thereafter.

However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below).

In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the “2019 Stock Option Plan”), which subsequently was amended in December 2020.

The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter.

However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder.

Scilex Holding Company 2022 Equity Incentive Plan

The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the “Equity Incentive Plan”) on October 17, 2022.

The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November 9, 2022.

The total number of common shares for which incentive stock options (“ISOs”) may be granted under the Equity Incentive Plan is not to exceed 14,622,712 shares plus a number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted under the Prior Plan (“Returning Shares”), if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) 4 % of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.

As of December 31, 2022, there were no options to purchase shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase 16,939,436 shares of the Common Stock were outstanding under previous plans.

In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the “Equity Incentive Plan”).

The total number of shares of Common Stock for which incentive stock options (“ISOs”) may be granted under the Equity Incentive Plan is not to exceed 20,276,666 shares, which was increased from 14,622,712 as a result of the automatic annual increase on January 1, 2023 pursuant to the Equity Incentive Plan provisions.

On May 4, 2023, the Company’s stockholders approved the amendment to the Equity Incentive Plan to (i) increase the number of shares authorized for issuance thereunder by 10,000,000 shares from 20,276,666 shares to 30,276,666 shares, (ii) increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 30,276,666 shares, and (iii) modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January 1, 2024.

As of December 31, 2023 , options to purchase 33,123,798 shares of Common Stock were outstanding under all equity incentive plans.

The Company recently determined that the aggregate value of all compensation granted or paid to each non-employee director for the fiscal year ending December 31, 2023 (when aggregated with any remaining compensation payable for the remainder of such fiscal year) would inadvertently exceed the $ 750,000 annual compensation limit for non-employee directors (the “Compensation Limit”) under the Equity Incentive Plan, as a result of the previously disclosed equity grants made thereunder to such non-employee directors in January 2023 (the “Awards”).

As a result, the Company’s current non-employee directors, David Lemus and Dorman Followwill, and the Company’s former non-employee directors, Tien-Li Lee and Laura Hamill, each voluntarily agreed to forfeit (i) a number of shares of Common Stock subject to their Awards or (ii) a combination of shares of Common Stock subject to their Awards and cash compensation payable by the Company for such person’s service as a director for the remainder of 2023, in each case in an amount that would bring each such non-employee director’s aggregate compensation for the fiscal year ending December 31, 2023 below the Compensation Limit.

The non-employee directors forfeited an aggregate of 311,735 shares of Common Stock and an aggregate of approximately $ 107,424 in cash compensation.

Scilex Holding Company 2023 Inducement Plan

On January 17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the “Inducement Plan”).

The Inducement Plan provides for the grant of equity-based awards in the form of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met.

The initial maximum number of shares available for grant under the Inducement Plan is 1,400,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions).

No awards were granted under the Inducement Plan during the year ended December 31, 2023.

The following table summarizes stock option activity during the year ended December 31, 2023 (shares in thousands):

Weighted-Average Exercise Price

Weighted-Average

Remaining Contractual Life,

Aggregate Intrinsic Value

Outstanding as of December 31, 2022

Forfeited/Cancelled

Outstanding as of December 31, 2023

Exercisable as of December 31, 2023

Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value.

The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2023 was $ 3.24 per share.

The total intrinsic values of options exercised during the years ended December 31, 2023, 2022, and 2021 were $ 1.1 million , $ 0.3 million , and nil, respectively.

Total stock-based compensation recorded within operating expenses was $ 14.6 million , $ 5.3 million and $ 5.8 million for the years ended December 31, 2023, 2022 and 2021, respectively.

The total unrecognized compensation costs related to unvested employee and non-employee stock option grants as of December 31, 2022 was $ 2.7 million and the weighted average period over which these grants are expected to vest is 1.4 years.

The total unrecognized compensation costs related to unvested employee and non-employee stock option grants as of December 31, 2023 were $ 42.4 million , which the Company expects to recognize over a weighted-average period of approximately 3.1 years.

Scilex Holding Company 2022 Employee Stock Purchase Plan

On October 17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the “ESPP”).

The ESPP was approved by the stockholders and became effective on November 9, 2022.

The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward the success of the Company.

The ESPP includes two components.

One component is designed to allow eligible U.S.

employees to purchase the Common Stock in a manner that may qualify for favorable tax treatment under Section 423 of the Internal Revenue Code of 1986 (“Code”) (the “423 Component”) and accordingly, it will be construed in a manner that is consistent with the requirements of Section 423 of the Code.

The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the “Non-423 Component”) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S.

while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by the Board, it will operate and be administered in the same manner as the 423 Component.

The Board administers the ESPP and will have the authority to determine how and when purchase rights are granted and the provisions of each offering.

Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed 1,462,271 shares of the Common Stock.

The number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of

(i) 1 % of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year;

(ii) 1,827,839 shares of the Common Stock;

and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.

As of December 31, 2022 , there were no shares outstanding under the ESPP.

Option Valuation

The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method.

The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant.

The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:

Year Ended December 31,

Weighted –average grant date fair value

In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the “ESPP”).

The purchase price of the Common Stock is equal to 85 % of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase.

As of December 31, 2023 , the total number of shares of Common Stock that may be issued under the ESPP shall not exceed 2,875,759 , which was increased from 1,462,271 shares as a result of automatic annual increase on January 1, 2023.

Total stock-based compensation recorded as operating expense for the ESPP was $ 21.0 thousand and nil for the year ended December 31, 2023 and 2022, respectively.

Valuation Assumptions

The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method.

The Black-Scholes option-pricing method requires the use of subjective assumptions.

The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP:

December 31, 2023

Stock options:

Expected dividend yield

Expected stock-price volatility

Expected volatility

40.00 % - 77.00 %

Risk-free interest rate

Term of options

Fair value per share of common stock on date of grant

Exercise price

3.59 % - 4.74 %

Term of options (in years)

Employee stock purchase plan:

Expected dividend yield

The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company’s common stock.

Expected stock-price volatility .

The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available.

The peer group was developed based on companies in the transdermal patch industry.

In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches.

Management further considered the development stage of the peer group companies.

Expected volatility

Risk-free interest rate

The Company bases the risk-free interest rate assumption on the U.S.

Treasury’s rates for U.S.

Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected term of options .

The expected term of options represents the period of time when options are expected to be outstanding.

Because the Company does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.

The following represents a summary of the options outstanding at December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):

Weighted average exercise price

Aggregate Intrinsic Value

Outstanding at December 31, 2019

Forfeited/Cancelled

Outstanding at December 31, 2020

Forfeited/Cancelled

Outstanding at December 31, 2021

Forfeited/Cancelled

Outstanding at December 31, 2022

Exercisable at December 31, 2022

Expected life (in years)

Employee Benefit Plan

The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento.

The Company maintains a defined contribution 401(k) plan available to eligible employees.

Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations.

The Company made matching contributions to the 401(k) plan totaling $ 0.3 million for each of the years ended December 31, 2022, 2021, and 2020 , respectively.

The Company made matching contributions to the 401(k) plan totaling $ 0.5 million , $ 0.3 million and $ 0.3 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Retainer Shares

On February 13, 2023, the Company entered into a Stock Issuance Agreement (the “SIA”) with a law firm for the provision of legal services to the Company.

Under the SIA, the Company issued 4,000,000 shares of Common Stock to the law firm (the “Retainer Shares”).

The Retainer Shares are held by the law firm as collateral for the current and future outstanding legal fees due from the Company.

At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees.

The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company.

As of December 31, 2023 , it was no t probable that any of the Retainer Shares would be applied against any outstanding legal fees.

Commitments and Contingencies

Product Development Agreement

In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the “Product Development Agreement”) with two parties (the “Developers”), one of which is ITOCHU CHEMICAL FRONTIER Corporation (“Itochu”), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103 (the “Products”), for Scilex Pharma.

In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the “Product Development Agreement”) with Itochu and Oishi Koseido Co., Ltd.

(“Oishi,” and together with Itochu, the “Developers”), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103 (the “Products”), for Scilex Pharma.

The Developers initially developed and have intellectual property rights relating to the Products.

2 unchanged sentences

Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25 % and 35 % to the Developers based on net profits .

During the year ended December 31, 2022, Scilex Pharma made royalty payments in the amount of $ 2.3 million .

As of December 31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $ 2.2 million .

For the years ended December 31, 2023 and 2022, Scilex Pharma made royalty payments in the amount of $ 8.3 million and $ 2.3 million .

As of December 31, 2023 and 2022, Scilex Pharma had ending balances of accrued royalty payables of $ 2.4 million and $ 2.2 million , respectively.

Total royalty expense recorded within cost of revenue was $ 8.5 million and $ 4.5 million for the years ended December 31, 2023 and 2022, respectively.

Net profits are defined as net sales, less cost of goods and marketing expenses.

Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S.

If Scilex Pharma were to sublicense the licensed technologies,

the Developers will receive the same proportion of any sublicensing fees received therefrom.

Net sales are defined as total gross sales of any Product, les s all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP.

If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom.

The Product Development Agreement will continue in full force and effect until October 2, 2028 , the date that is ten years from the date of the first commercial sale of ZTlido.

The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.

On February 16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the “Supply Agreement”) with the two Developers to provide commercial supply of ZTlido and SP-103 to Scilex Pharma.

The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply.

In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.

Exclusive Distribution Agreement

In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the “Distribution Agreement”) to appoint an exclusive third-party logistics distribution provider (the “Distributor”) and as an authorized distributor of record of ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a 3 % annual adjustment.

The Distribution Agreement has an initial term of three years following the first shipment of FDA-approved Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term .

In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor’s negligence or willful misconduct.

Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor’s facility, including all costs, expenses and risk of loss associated with such delivery.

From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between 1 % to 2 % which was recorded as a gross-to-net sales adjustment.

As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022.

The Company currently holds all necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022.

Sales Operations Services

In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the “Project Agreement”).

In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets.

These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor.

In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.

On July 1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma.

The vendor continued to provide sales operations services, fleet management services and sample accountability services.

The work order was in effect until June 30, 2022 and was extended for one year upon the mutual agreement of both parties.

Either party may terminate the work order with 90 days’

Scilex Pharma paid

an implementation fee of $ 59 .0 thousand and will pay fixed monthly fees of $ 63.7 thousand to $ 65.8 thousand for ongoing services.

The Company recognized an expense of $ 0.9 million , $ 1.9 million, and $ 10.5 million within selling, general and administrative expenses for services performed for the years ended December 31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs.

In the normal course of business, the Company may be named as a defendant in one or more lawsuits.

Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.

Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company’s financial condition or results of operations.

From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business.

1 unchanged sentence

LLC and Hisamitsu America, Inc.

On February 23, 2021, the Company filed an action in the U.S.

On February 23, 2021, the Company filed an action (the “Action”) in the U.S.

District Court for the Northern District of California against Sanofi-Aventis U.S.

LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the “Sanofi-Aventis & Hisamitsu Litigation”).

This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products.

The defendants have filed motions to dismiss, which have narrowed slightly the Company's claims, but which motions the court has largely rejected.

Discovery is proceeding.

The case is currently scheduled for trial to begin on July 24, 2023.

The Company cannot make any predictions about the outcome in this matter or the timing thereof.

Former Employee Litigation

On March 12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc.

(“Virpax”), a company now headed by Mr.

LLC and Hisamitsu America, Inc., two manufacturers of over-the-counter (“OTC”) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products.

This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products.

The defendants filed motions to dismiss, which narrowed slightly the Company’s claims, but which motions the court largely rejected.

Discovery was proceeding.

On January 26 and February 2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action.

The terms of those agreements are confidential.

Former Employee Action

On March 12, 2021, Scilex Pharma and Sorrento (the “Plaintiffs”) filed an action (the “Former Employee Action”) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc.

(“Virpax”, together with Mr.

Mack, the “Defendants”), a company founded and then headed by Mr.

Mack, alleging, among other things, breach by Mr.

Mack of his non-compete agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that non-compete agreement (the “Former Employee Litigation”).

This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.

Mack from further violating his non-compete agreement and enjoining Virpax from tortiously interfering with Mr.

Mack’s non-compete agreement.

Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.

Mack’s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma’s trade secrets by Mr.

Mack and Virpax.

Such lawsuit sought, among other relief, damages and various forms of injunctive relief.

The case was tried from September 12, 2022 to September 14, 2022.

Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court.

The Company cannot make any predictions about the outcome in this matter or the timing thereof.

On September 1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived.

In its 95-page opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings.

On October 18, 2023, the Plaintiffs submitted a supplemental brief on remedies.

On November 29, 2023, Defendants submitted a supplemental brief on remedies.

On December 21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies.

On February 26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes.

On February 29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax will be obligated to make the following payments to the Company to settle the Former Employee Action:

(i) $ 3.5 million (the “Initial Payment”) by two business days after the Effective Date (as defined therein);

(ii) $ 2.5 million by July 1, 2024 and (iii) to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6 % of annual Net Sales (as defined therein) of Epoladerm;

(b) 6 % of annual Net Sales of Probudur and (c) 6 % of annual Net Sales of Envelta during the Royalty Term (as defined therein).

The Company and Virpax provide mutual releases of all claims that exist as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action.

Plaintiffs’ release relates to claims against Virpax only, which does not affect its claims against Mr.

Plaintiffs have not released Mr.

Mack, and litigation against him remains ongoing.

Plaintiffs’ release as to Virpax is conditioned upon Virpax’s Initial Payment.

ZTlido Patent Litigation

On June 22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc.

(together, “Apotex”) in the U.S.

District Court for the Southern District of Florida (the “ZTlido Patent Litigation”) alleging infringement of certain Orange Book listed patents covering ZTlido (the “ZTlido Patents”).

The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out

in the Hatch-Waxman Act, of an ANDA.

Apotex’s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed.

The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex’s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate.

On June 22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc.

(“Aveva”), Apotex Corp., and Apotex, Inc.

(together, “Apotex”) in the U.S.

District Court for the Southern District of Florida (the “ZTlido Patent Litigation”) alleging infringement of certain Orange Book listed patents covering ZTlido (the “ZTlido Patents”).

The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (“ANDA”).

Apotex is subject to a 30-month stay preventing it from selling a generic version of ZTlido during that time.

The stay should expire no earlier than November 11, 2024.

Trial in the ZTlido Patent Litigation has not yet been scheduled.

The two Apotex entities were recently dismissed from the litigation without prejudice, as they no longer have an interest in the generic product that Aveva

seeks to market.

Trial in the ZTlido Patent Litigation has been scheduled for July 8, 2024.

The Company cannot make any predictions about the final outcome of this matter or the timing thereof.

GLOPERBA Patent Litigation

On November 6, 2023, Takeda Pharmaceuticals U.S.A., Inc.

(“Takeda”) filed a complaint against the Company in the U.S.

District Court for the District of Delaware (the “GLOPERBA Patent Litigation”) alleging that the Company’s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda’s colchicine product, Colcrys ® (the “Colcrys Patents”).

Takeda is seeking an order that the effective date of any FDA approval of the Company’s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate.

The filing of the complaint subjects the Company to a 30-month stay, preventing it from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time.

The Company cannot make any predictions about the final outcome of this matter or the timing thereof.

The stay could last as long as until May 6, 2026, unless the litigation is resolved before that time .

As of December 31, 2023, the Company accrued $ 0.5 million with respect to the GLOPERBA Patent Litigation.

Operating Leases

1 unchanged sentence

Facility leases generally provide for periodic rent increases and may include options to extend.

As of December 31, 2022, the Company’s leases have remaining lease terms of approximately 1.6 to 1.9 years.

The term of the Company’s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from 3 to 5 years.

Many of the Company’s leases are subject to variable lease payments.

Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the right-of-use assets or lease liabilities and are immaterial.

As of December 31, 2023, the Company’s leases have remaining lease terms of approximately 0.7 to 3.8 years.

Th e terms of the Company’s leases, ranging from 3 to 5 years, include extension options that were not reasonably certain to be exercised.

Many of the Company’s leases are subject to variable lease payments.

Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial.

Additionally, the Company subleases certain properties to third parties.

Sublease income is recognized on a straight-line basis and is immaterial.

As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.

The Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.

The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.

As of December 31, 2023 , the Company has no finance leases .

The components of lease expense were as follows (in thousands):

Year Ended December 31,

Operating lease cost*

* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial

for the periods presented.

In April 2023, the Company modified the lease term for its principal executive offices located in Palo Alto, California.

The modification extended the lease term for an additional three years, with the lease term expiring in September 2027.

As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $ 2.5 million .

Lease expense was $ 1.1 million , $ 0.5 million and $ 0.6 million for the years ended December 31, 2023, 2022 and 2021, respectively, and was primarily comprised of operating lease costs.

The lease expense also included variable lease costs and sublease income, which were immaterial for the periods presented.

Supplemental quantitative information related to leases includes the following:

1 unchanged sentence

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases

ROU assets obtained in exchange for new operating lease liabilities

Weighted average remaining lease term in years —

operating leases

Weighted average discount rate —

operating leases

In June 2022, the Company entered into a new non-cancelable lease agreement for an administrative facility in Palo Alto.

The lease includes annual rent increases and the option to extend.

The term of the new lease is 26 months and the Company does not expect to exercise the extension option at the end of the lease.

Operating cash flows from operating leases (in thousands)

Weighted average remaining lease term in years — operating leases

Weighted average discount rate — operating leases

Approximate future minimum lease payments under operating leases were as follows (in thousands):

14 unchanged sentences

Changes in valuation allowance

Total income tax benefit from continuing operations

Total income tax expense from continuing operations

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

The components of the Company’s net deferred tax liabilities and related valuation allowance are as follows as of December 31, 2022 and 2021 (in thousands):

The components of the Company’s net deferred tax liabilities and related valuation allowance are as follows as of December 31, 2023 and 2022 (in thousands):

Year Ended December 31,

16 unchanged sentences

The reconciliation between U.S.

federal income taxes at the statutory rate and the Company’s provision for income taxes are as follows for the years ended December 31, 2022, 2021, and 2020 (in thousands):

federal income taxes at the statutory rate and the Company’s provision for income taxes are as follows for the years ended December 31, 2023, 2022 and 2021 (in thousands):

Year Ended December 31,

6 unchanged sentences

State, net of federal tax benefit

Income tax credits and incentives

Income tax benefit

Change in fair value of Convertible Debentures

Change in tax rates

Income tax expense

The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized.

2 unchanged sentences

As of December 31, 2023, the Company had $ 278.7 million and $ 114.0 million of federal and state net operating loss carryforwards, respectively.

The net operating loss carryforwards begin to expire in 2035 and 2034 for federal and

state, respectively.

The Company also had federal research and development income tax credits of $ 2.0 million which will begin to expire in 2035 .

The net operating loss carryforwards begin to expire in 2035 and 2034 for federal and state, respectively.

As of December 31, 2023, the Company had a total of $ 265.9 million of federal net operating losses that have an indefinite life and will not expire, and had federal research and development income tax credits of $ 3.4 million which will begin to expire in 2035 .

As of December 31, 2023, the Company had California research and development income tax credits of $ 1.9 million that have an indefinite life and will not expire.

Internal Revenue Code Section 382 rules apply to limit a corporation’s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section 382.

For the years ended December 31, 2022 and 2021, there was no impact of such limitations on the Company’s income tax provision.

For the years ended December 31, 2023 and 2022, there was no impact of such limitations on the Company’s income tax provision.

The Company is subject to taxation in U.S.

federal and state tax jurisdictions.

All of the Company’s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss.

There are no active tax compliance audits as of December 31, 2023.

2 unchanged sentences

Increase related to prior year tax positions

Decrease related to prior year tax positions

Increase related to current year tax positions

Increases related to current year tax positions

Ending balance

At December 31, 2022, 2021, and 2020, $ 0.4 million , $ 0.4 million and $ 0.4 million, respectively, of the Company’s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil.

The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense.

As of December 31, 2023, 2022 and 2021, the Company had $ 1.1 million , $ 0.4 million and $ 0.4 million in total unrecognized tax benefits, respectively.

If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil.

The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense.

No interest or penalties have been recognized as of and for the periods ended December 31, 2023, 2022 and 2021.

The Company believes that no material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of December 31, 2023 .

Related Party Transactions

As of December 31, 2020, approximately 14.7 % of the outstanding capital stock of the Company was held by Itochu.

On January 13, 2021, 34,889,868 shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by non-related minority shareholders.

Thus, Itochu is not a shareholder subsequent to January 13, 2021.

During the years ended December 31, 2022, 2021, and 2020 the Company purchased approximately $ 6.7 million , $ 5.7 million, and $ 1.0 million respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement.

These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company’s statement of operations.

Semnur is party to an Assignment Agreement, dated August 6, 2013 (the “Assignment Agreement”), with Shah Investor LP (“Shah Investor”).

Mahendra Shah, Ph.D., who has served on the Company’s board of directors since March 2019, is the managing partner of Shah Investor.

Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the low-single digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by

injection developed using such intellectual property, which would include SP-102.

Through December 31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.

On January 1, 2017, a Transition Services Agreement (“TSA”) was executed between Scilex Pharma and Sorrento.

Pursuant to the TSA, Sorrento agreed, at the Company’s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services.

In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company.

During the years ended December 31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $ 3.8 million , $ 4.0 million, and $ 2.3 million, respectively.

On March 18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $ 16.5 million for the acquisition of Semnur.

The note is interest bearing at the lesser of (a) 10 % simple interest per annum, and (b) the maximum interest rate permitted under law.

Interest is due and payable annually.

The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium.

During the years ended December 31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $ 27.5 million , $ 6.6 million, an d $ 13.7 million respectively, under the note payable.

All outstanding related party indebtedness immediately prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November 10, 2022 (see Note 12).

The outstanding principal balance of the note on November 10, 2022 and December 31, 2021 was $ 47.1 million and $ 19.6 million, respectively, which was recorded under the current related party note payable in the Company’s consolidated balance sheets.

As of November 10, 2022 and December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $ 7.2 million and $ 3.9 million, respectively, which was recorded under related party payable in the Company’s consolidated balance sheets.

The proceeds from the note payable were used to finance the operations of the Company.

On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $ 21.7 million for certain amounts previously advanced to Scilex Pharma by Sorrento (the “Intercompany Note”).

Scilex Pharma may borrow up to an aggregate of $ 25.0 million of principal amount under the note payable.

The promissory note is interest bearing at the lesser of (a) 10 % simple interest per annum, and (b) the maximum interest rate permitted under law.

All outstanding principal amounts and accrued interest was due upon maturity on August 31, 2026 .

On October 22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment of $ 21.7 million of indebtedness under this promissory note.

During the years ended December 31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $ 0 , $ 8.1 million, and $ 10.3 million respectively, under the promissory note.

As of November 10, 2022 and December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $ 5.1 million and $ 3.1 million, respectively, which was recorded under related party payable in the Company’s consolidated balance sheets.

As of November 10, 2022 and December 31, 2021, Scilex Pharma’s outstanding principal balance under the promissory note was $ 23.5 million , which was recorded under the non-current related party note payable in the Company’s consolidated balance sheets.

The Company received $ 35.0 million in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7.

The $ 35.0 million received in February 2022 was due no earlier than February 2030 and was recorded under the non-current related party note payable in the Company’s consolidated balance sheets as of November 10, 2022.

Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company’s consolidated balance sheets.

As of November 10, 2022, related party payables due to Sorrento included

$ 61.7 million to cover working capital requirements, $ 100.0 million for repurchases of Scilex Pharma Notes, and $ 18.2 million for litigation fees (see Note 7).

As of December 31, 2021 , related party payables due to Sorrento consisted of $ 35.7 million to cover working capital requirements, $ 51.0 million for repurchases of Scilex Pharma Notes, and $ 6.0 million to pay litigation fees.

As of December 31, 2022, the Company had a $ 1.8 million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14).

On May 12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3).

Pursuant to the Bill of Sale, the Company assumed all of Sorrento’s rights, liabilities and obligations under Aardvark Asset Purchase Agreement.

The Company issued the 2022 Promissory Note to Sorrento as consideration transferred.

As of November 10, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $ 4.2 million , which was recorded under the non-current related party note payable in the Company’s consolidated balance sheets.

Debt Exchange Agreement

On September 12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the “Debt Exchange Agreement”) with Sorrento, pursuant to which (i) Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the “Aggregate Outstanding Amount”

or “Outstanding Indebtedness”), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $ 27.5 million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii) the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii) upon the occurrence of the events described in clauses (i) and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.

Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of preferred stock, par value $ 0.0001 per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the “Exchange Shares”

and such transaction, the “Debt Contribution”) that is equal to (i) the Aggregate Outstanding Amount plus the amount equal to 10 % of the Aggregate Outstanding Amount divided by (ii) $ 11.00 (rounded up to the nearest whole share);

provided, that in no event would the Aggregate Outstanding Amount exceed $ 310,000,000 .

On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento totaling $ 290.6 million was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement.

This amount was converted to 29,057,097 shares of Scilex Preferred Stock and 2,905,710 shares of the Company's Common Stock.

Loss Per Share

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share .

The Company has two classes of shares, which are referred to as Common Stock and Preferred Stock.

Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities.

Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.

The retroactive adjustment is based on the same number of weighted average shares outstanding in each historical period.

For the years ended December 31, 2022, 2021, and 2020, basic loss per share is computed using the two-class method.

The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings.

Preferred Stock is not contractually required to share in net losses of the Company.

Net Loss Per Share

The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December 31, 2023, 2022 and 2021 (in thousands except per share data):

Year Ended December 31,

Net loss attributable to Scilex

Net loss attributable to participating securities

Net loss attributable to common stockholders

Weighted average common shares outstanding

Premium on redemption of Preferred Stock

Net loss for basic and diluted loss per share available to common stockholders

Weighted average number of shares outstanding - basic

Effect of dilutive securities

Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities

Basic and Diluted Loss Per Share

Weighted average number of shares and assumed conversions - diluted

Loss per share

Basic and diluted

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period.

Premium paid on redemption of Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the preferred stockholder.

Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period.

Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method).

In the computation of net loss per share, treasury shares are not included as part of the outstanding shares.

In accordance with FASB ASC 260, Earnings Per Share, Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share.

The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September 21, 2023.

The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September 21, 2023 and the vesting is based on the passage of time, the Company’s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined

Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time.

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:

Year Ended December 31,

Stock options

1 unchanged sentence

Private Warrants

Retainer Shares

Shares Issuable pursuant to ESPP

Convertible Debentures

Subsequent Events

The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December 31, 2022.

Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure.

Riley Standby Equity Purchase Agreement

On January 8, 2023, the Company entered into a Standby Equity Purchase Agreement (the "B.

Riley Purchase Agreement") with B.

Riley, whereby the Company shall have the right, but not the obligation, to sell to B.

Riley up to $ 500.0 million of its shares of the Company’s Common Stock at the Company's request any time during the 36 months following the execution of the B.

Riley Purchase Agreement, subject to certain conditions.

The Company expects to use the net proceeds received from this for working capital and general corporate purposes.

As consideration for B.

Riley’s commitment to purchase shares of Common Stock at the Company’s direction upon the terms and subject to the conditions set forth in the B.

Riley Purchase Agreement, the Company issued 250,000 shares of Common Stock to B.

Riley in connection with the execution of the B.

Riley Purchase Agreement on January 12, 2023.

Subsequent to the execution of the B.

Riley Purchase Agreement, the Company sold an aggregate of 127,241 shares of Common Stock pursuant to the B.

Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $ 1 million.

Scilex Holding Company 2023 Inducement Plan

On January 17, 2023, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the “Plan”).

The Plan will serve to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in the Company.

The Plan provides for the grant of equity-based awards in the form of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.

The initial maximum number of shares available for grant under the Plan is 1,400,000 shares of the Company’s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions).

Amendment to the Yorkville Purchase Agreement

On February 8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the “A&R Yorkville Purchase Agreement”), amending, restating and superseding the Yorkville Purchase Agreement dated November 17, 2022.

Pursuant to the A&R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville.

Subsequent to December 31, 2022, the Company sold an aggregate of 85,000 shares of Common Stock pursuant to the A&R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $ 0.6 million.

Elyxyb License

On February 12, 2023, the Company acquired from BioDelivery Sciences International, Inc.

(“BSDI”) and Collegium Pharmaceutical, Inc.

(“Collegium”, and together with BDSI, the “Collegium Sellers”) the rights to certain patents,

trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the “Product”) and its commercialization in the United States and Canada (the “Territory”).

As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated August 3, 2021 (the “DRL APA”), between BDSI and Dr.

Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory.

Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to know-how related to the Product and necessary or used to exploit the Product in the Territory.

No cash consideration was or will be payable to Collegium Sellers for such acquisition;

however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales of the Product in the Territory for all indications and additional amounts if certain milestones are achieved.

Sorrento Chapter 11 filing

On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas.

While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento’s voluntary Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual.

As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which was fully reserved.

Termination of B.

Riley Purchase Agreement

On February 16, 2024, the Company and B.

Riley mutually agreed to terminate the B.

Riley Purchase Agreement.

The termination is effective as of February 16, 2024.

Underwritten Offering

On February 29, 2024, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Rodman & Renshaw LLC and StockBlock Securities LLC, as the representatives (the “Representatives”) of the underwriters named in Schedule A (the “Underwriters”).

Pursuant to the Underwriting Agreement, the Company agreed to sell, in an underwritten offering (the “Bought Deal Offering”), 5,882,353 shares (the “Firm Shares”) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 5,882,353 shares of Common Stock (the “Firm Warrants”).

Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to 882,352 additional shares of Common Stock (the “Optional Shares”, and together with the Firm Shares, the “Shares”) and/or common warrants to purchase up to 882,352 shares of Common Stock (the “Optional Warrants”, and together with the Firm Warrants, the “Common Warrants”) that may be purchased by the Underwriters, at a price per Optional Share of $ 1.5548 and a price per Optional Warrant of $ 0.0092 , which amounts reflect the public offering price of $ 1.69 per Optional Share and $ 0.01 per Optional Warrant, less underwriting discounts and commissions, as applicable (the “Underwriters’ Option”).

Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $ 1.70 .

The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $ 1.564 , which amount reflects the combined public offering price of $ 1.70 , less underwriting discounts and commissions.

Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $ 1.70 per share.

The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock.

In connection with the Bought Deal Offering, the Company agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the “Representative Warrants”, and together with the Common Warrants, the “Warrants”) to purchase up to an aggregate of 470,588 shares of Common Stock (which represents 8.0 % of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of 541,176 shares of Common Stock if the Underwriters exercise the Underwriters’ Option in full.

The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $ 2.125 per share, which represents 125 % of the combined public offering price per Firm Share and accompanying Firm Warrant.

The Company also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and out-of-pocket expenses up to $ 200,000 and up to $ 15,950 for clearing expenses.

The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form S-3, which was originally filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2023, as amended, and was declared effective on January 11, 2024 (File No.

333-276245), a base prospectus dated January 11, 2024, and a final prospectus supplement dated February 29, 2024.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures